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Chronic Myelogenous Leukemia (CML) is a hematopoietic cancer caused by the 
formation of the Philadelphia chromosome, a reciprocal translocation of the ABL1 
oncogene on chromosome 9, and the breakpoint cluster region gene (BCR) chromosome 
22, resulting in the BCR-ABL oncoprotein. BCR-ABL is a constitutively active tyrosine 
kinase that regulates cell growth and differentiation, leading to uncontrolled cell 
proliferation by deregulating downstream signaling pathways.  
 A revolution in cancer treatment was ushered in with the introduction of 
imatinib mesylate (Gleevec®), an ATP-competitive inhibitor specific to BCR-ABL which 
traps the oncoprotein in its inactive conformation, leading to its degradation. Imatinib 
validated small-molecule kinase inhibitors as promising candidates for cancer therapy. 
However, a small but significant portion of CML patients is intrinsically resistant to 
imatinib, and others develop resistance over time. Mutations in the kinase domain 
preventing drug binding are partially responsible for resistance, but in many patients, no 




been developed which inhibit BCR-ABL even in the presence of kinase domain mutations 
conferring resistance to imatinib, but resistance to both second-generation tyrosine 
kinase inhibitors (TKIs) has been reported. We have developed lines of K562 cells 
resistant to imatinib (K562-IR), nilotinib (K562-NR), and dasatinib (K562-DR), 
respectively. We used a proteogenomic approach, bridging transcriptomics with 
proteomics to attempt to unravel the mechanisms underlying TKI-resistance and 
identify potential biomarkers of TKI-resistance in CML. We identified significant 
increased protein expression in proteins involved in cell proliferation, and a reduction of 
the proteins involved in protein translation across all three TKI-resistant cell lines, and 
also identified novel fusion genes present in our TKI-resistant cell lines that could 





CHAPTER 1. INTRODUCTION 
1.1 The Cell and Cancer 
1.1.1 Cellular Signaling Controls Cell Functions 
The cell is basis of all human life, and constantly adapts to its environment. The cell 
reacts to external or internal stimuli through intricate molecular signaling pathways that 
can take the form of protein-protein interactions, ligand-receptor interactions, post-
translational modifications, or protein-DNA interactions, and others, all of which can 
effect downstream gene expression, allowing the cell to properly respond to stimuli. The 
ability to sense and react to stimuli ensures proper cell differentiation and proliferation, 
and allows the cell to undergo apoptosis before attaining deleterious properties. This 
process continues to form tissues, and organs, and the cells comprising these tissues 
and organs communicate through cell-cell interactions composed of molecular signals.  
Molecular signaling is critical to maintain cellular homeostasis. Cells must regulate the 
influx and efflux of proteins, ATP, and ions, the internal pH of the cell, and neutralize 
free radicals, which can damage DNA. Cellular proliferation is also regulated by 
molecular signaling events that are coordinated throughout the cell cycle. A system of 
molecular checks and balances ensures that cells proliferate properly, and undergo the 





functions of that cell. Regulation of many processes at once requires integration of 
many signaling inputs, and a coordinated response of outputs that allows the cell to 
maintain its properties and perform its functions. While this process is unfathomably 
dynamic, it is also very delicate. 
 
1.1.2 Cell Signaling and Mutation 
Genetic mutation has wide-ranging effects on the ability of the cell to sense and adapt 
to its environment, and is necessary for the progress of evolution to proceed. There are 
many types of mutations, which can have varying phenotypic consequences ranging 
from null consequences to developmental abnormalities and organismal death. A loss-
of-function mutation produces an inactive gene product, and is often recessive in 
diploid organisms because another copy of the gene is present and can compensate for 
the loss of function[1]. A gain-of-function mutation strengthens the effect of the gene 
product, and is known as an activating mutation[2]. Dominant-negative mutations are 
mutations that cause the mutant gene product to have an antagonistic effect on the 
wild-type gene. Dominant-negative mutations have been implicated in oncogenesis, 
such as the mutations found in the tumor-suppressing protein p53[3]. Mutations in p53 
have been found in many tumors, and inhibition of p53 function has been shown to 
increase invasiveness, metastasis, and overall tumor growth by changing the activation 





Genetic mutations can arise in many ways, such as errors in DNA replication, or through 
external environmental factors such as exposure to UV light from the sun causing DNA 
damage[1, 2, 4-7]. A frameshift mutation arises from an insertion or deletion of a 
nucleotide or nucleotides in the gene encoding a protein, and changes the ensuing 
amino acid sequence by shifting the codon sequence produced, leading to dramatic 
changes in the composition of the protein eventually translated from the mRNA 
produced by the gene[8]. A nonsense mutation occurs when a mutation in a gene 
encodes for a premature stop codon, leading to the translation of a truncated protein[9]. 
Missense mutations occur when a point mutation a gene changes the codon produced, 
and the resulting amino acid sequence is altered only at the codon affected by the 
missense mutation[5, 10]. There are also neutral and silent mutations. Neutral 
mutations occur when alteration of the genetic code encodes for a chemically similar 
amino acid, such as the substitution of an arginine residue for a lysine residue[11]. A 
silent mutation refers to a mutation producing the same amino acid, despite the 
presence of a mutated nucleotide residue[12].  
 
The mutation of an amino acid residue can disrupt the balance of complex molecular 
signaling networks by encoding for an inactive protein, an overactive protein, or a 
protein that otherwise alters the ability of the cell to sense and react to its environment 
such as the ability of the protein to bind other proteins or DNA. Mutation can also occur 





Rearrangements of whole chromosomes can even occur, leading to novel genetic 
products. The generation of a novel gene due to the juxtaposition of two genes normally 
found in distant positions on the same chromosome or entirely different chromosomes 
is known as chromosomal translocation[13-19], which can result in genetic products 
that can be translated into mutant fusion proteins if open reading frames are preserved. 
Conversely, a situation that results in the deletion of a gene is known as an interstitial 
deletion[20], whereas the reversal of gene orientation is known as an inversion[21]. 
Mutations at the chromosomal level are equally capable of leading to disease 
pathologies as mutations at the amino acid level, particularly when fusion proteins are 
produced or critical genes are deleted. The consequences of mutation are variable, but 
many diseases arise from mutations altering the ability of genes important in molecular 
signaling to maintain homeostasis.  
 
1.1.3 Genetic Mutation and Cancer 
The term cancer refers to a collection of diseases characterized by uncontrolled cellular 
proliferation, resistance to apoptosis, evasion of growth suppression, increased 
angiogenesis, enabling replicative immortality, invasion and metastasis, reprograming of 
energy metabolism, and the ability to avoid immune detection[22]. The underlying 
cause of cancer is genomic instability, which compromises the ability of the cell to sense 
and properly react to its environment. Mutation of genes involved in the regulation of a 





damage response can cause oncogenesis[22]. The mutation of one protein in a complex 
signaling system can have wide-ranging effects that drive unchecked proliferation. A 
notable example of this is the mutation of the protein B-RAF, which occurs in about 66% 
of human melanomas. The protein RAS binds to a serine-threonine kinase RAF, 
activating RAF. RAF phosphorylates MEK, which phosphorylates a MAP kinase, which 
phosphorylates several transcription factors that activate transcription of genes critical 
to driving cell proliferation. One of these genes is the kinase EphA2, which 
phosphorylates p120RasGAP, which in turn downregulates wild-type RAS as a negative 
feedback mechanism to control the rate of cell proliferation[23-25]. However, mutant 
RAS is not downregulated, and the signaling cascade can proceed unchecked. Many 
other targets of the MAPK pathway are also affected, including repression of apoptotic 
signals, cell-cycle checkpoints, and cell division machinery. Despite the fact that cancer 
is caused by genomic instability, there are currently no methods to directly target the 
genetic instability underlying cancer progression, we must overcome this limitation by 
targeting the protein products of genomic instability.  
 
1.1.4 Therapeutic Strategies in Cancer 
Initial attempts to treat cancers using chemicals were considered largely successful at 
the time. The first use of chemicals in cancer therapy (chemotherapy) was in 1942, 
when Louis Goodman and Alfred Gilman used nitrogen mustards; a derivative of the 





tumor in a patient being treated for non-Hodgkins lymphoma[26]. This was the first 
demonstration that cancer could be treated with pharmacological agents. Sidney Farber 
expanded on the discoveries of Goodman and Gilman in 1948, when he used the 
antifolate derivatives aminopterin and methotrexate to treat children with acute 
lymphoblastic leukemia (ALL)[27]. Because ALL is a disease of white blood cells, it is 
possible to directly measure the effect of chemotherapy by simply drawing blood and 
counting the depletion of cells over the course of treatment, and his highly controversial 
report in the New England Journal of Medicine piqued interest in the development of 
new pharmacological agents as anti-cancer therapies. At the time, little was known 
about the molecular biology of cancer. Accordingly, many cancer treatments developed 
then would be deemed barbaric by today’s standards due to the fact that none of the 
treatments selectively targeted cancer cells. Other strategies for treating patients with 
cancer were based on the rationale that by developing treatments biased toward rapidly 
proliferating cells, one could kill all cancer cells before killing the patient. The evolution 
of cancer treatments progressed with the realization that disruption of the 
incorporation of nucelosides into a new strand of DNA would cause cells to undergo 
apoptosis, and the drug 6-mercaptopurine, which eventually became incorporated into 
DNA as a 6-thioguanine nucleotide, was discovered to be highly effective at treating 
leukemias[28]. With new therapies came undesirable side effects, and new forms of 
therapy targeting diverse aspects of cancer hallmarks were conceived. Vinca alkaloids 
were next developed, which inhibit microtubule polymerization and consequently 





as paclitaxel, which inhibit the breakdown of microtubules leading to inhibition of cell 
division, topoisomerase I inhibitors such as camptothecin, which prevents DNA re-
ligation during DNA synthesis leading to apoptosis, platinum-containing cancer drugs 
such as cisplatin, which induces irreparable DNA damage by cross-linking to DNA leading 
to apoptosis, and alkylating agents such as cyclophosphamide, which inhibit DNA 
synthesis by cross-linking DNA strands leading to apoptosis[29-33]. All of these therapies 
were effective to an extent, but the side effects of untargeted therapies, such as fatigue, 
loss of appetite, sexual dysfunction, neuropathy, and organ damage were devastating 
for many cancer patients. Better therapies were needed to directly treat the many 
different causes of cancer.  
 
In the 1990’s it was recognized that the growth of some breast cancers was partially 
dependent on the hormone estrogen. Estrogen binds to a receptor (estrogen receptor, 
ER) on breast cells and activates an intracellular molecular signaling cascade promoting 
breast cancer cell proliferation. To combat this critical signaling event, Tamoxifen, a drug 
developed in the 1960’s as a potential emergency contraceptive was repurposed as an 
anti-estrogen compound. Tamoxifen is a prodrug that is metabolized by cytochrome 
P450 isoforms CYP2D6 and CYP3A4 in the liver to yield the active metabolites 4-
hydroxytamoxifen and N-desmethyl-4-hydroxytamoxifen, which bind the ER on breast 
cancer cells with high affinity, blocking estrogen from binding to its receptor. The ER/4-





the expression of genes driving cell proliferation[34]. The introduction of a molecule 
that blocked molecular signaling as a breast cancer treatment was a crucial step toward 
recognizing the need for targeted therapies in cancer treatment. An understanding of 
the underlying molecular machinery driving cancer progression was sorely lacking, and 
without a fundamental understanding of the driving forces behind cell proliferation, the 
development of targeted therapies was inefficient and ineffective.   
 
1.1.5 Molecular Signaling and Cancer 
Cancer is a disease that is characterized by uncontrolled cell proliferation, and the 
proliferation of healthy cells is tightly controlled by a system of checks and balances. 
Highly intertwined molecular signaling networks communicate by receiving and 
integrating signals from extracellular growth factors, cell-cell contact, and other 
intracellular signaling networks to regulate cell proliferation, protein synthesis, DNA 
synthesis, energy metabolism, and apoptosis[2, 24, 25, 35-38]. Disruption of these 
signals can cause an imbalance in the downstream signaling events, which are reliant on 
the information obtained from upstream signals. An imbalance in a signaling network 
propagates throughout the network and cells that cannot correct for imbalances can 
attain the characteristic properties of cancer, such as unregulated cell growth. A 
prominent molecular signaling mechanism is the enzyme-catalyzed transfer of a 
phosphate group from the active site of an enzyme known as a kinase to the desired 





control cell differentiation, proliferation, and apoptosis, and the 520 kinases make up 
approximately 2% of the human genome. There are two major classes of protein kinases, 
those that preferentially phosphorylate serine and threonine residues, and those that 
preferentially phosphorylate tyrosine residues.  Serine/threonine kinases comprise 
approximately 80% of the protein kinases in the human genome, and although tyrosine 
kinases comprise about 20% of human protein kinases, tyrosine residues represent only 
about 1.8% of the phosphorylated residues in the human body[40]. Despite the 
dramatic difference in abundance, tyrosine kinases are tremendously important in cell 
signaling.  
 
Tyrosine kinases are composed of two different sub-classes of protein kinases. Non-
receptor tyrosine kinases (NRTK) which are free to roam about the intracellular space of 
the cell, and receptor tyrosine kinases (RTK), membrane-bound kinases activated by a 
ligand binding to the extracellular surface of the cell, which transduce extracellular 
signals into intracellular signals.[40-43]. Most RTKs exist as monomeric subunits, but 
others consist of multimeric units that work together to convert extracellular signals to 
intracellular signals. For example, the insulin receptor (IR) is a tyrosine kinase that plays 
a critical role in the regulation of glucose homeostasis. During transcription, alternative 
splicing leads to two isoforms of the gene, IR-A and IR-B. Downstream post-translational 
modification of the IR-A and IR-B protein products leads to α and β subunits, which can 






complex can bind insulin, Insulin-like Growth Factor I (IGF-I), and Insulin-like Growth 
Factor II (IGF-II). Binding of the ligand causes a conformational change in the dimer, 
resulting in autophosphorylation of the intracellular tyrosine residues on the β chain of 
the tyrosine kinase domain[44]. Phosphorylation of the tyrosine residues recruits 
adaptor proteins such as insulin receptor substrate (IRS) proteins, SH2-B domains, and 
phosphatases such as PTP1B to the tyrosine kinase domain, which regulate the 
downstream processes required to maintain glucose homeostasis[45].  In contrast, 
NRTKs are unbound and are free to move around the intracellular space freely. A well-
known example of a NRTK is Ableson protein tyrosine kinase 1, also known as c-Abl. c-
Abl has many diverse functions in the cell, such as cytoskeleton remodeling in response 
to extracellular stimuli, cell motility and adhesion, receptor endocytosis, autophagy, 
DNA damage response and apoptosis. c-Abl is typically found in the cytoplasm, but can 
be shuttled into the nucleus through protein-protein interaction with 14-3-3 scaffold 
proteins, and upon nuclear translocation, c-Abl is able to bind DNA and is involved in the 
DNA damage response, and activation of pro-apoptotic pathways if the damage to DNA 
is too much for the cell to survive[46].  
 
Tyrosine kinases are ubiquitously expressed in many cell types, and have been 
prominently implicated in the progression of cancer. Janus kinase 2 (JAK2) is a NRTK in 
the cytokine type II receptor family that is critical to IL-3 receptor signaling, driving 






factors in the cytoplasm, and consequently the STAT transcription factors translocate to 
the nucleus and activate transcription of genes such as SOCS3, a negative regulator of 
RasGRP. RasGRP is a negative regulator of RAS, so the JAK2/STAT pathway indirectly 
activates the RAS pathway[47]. In several myeloproliferative disorders, JAK2 contains an 
activating mutation where the valine at the 617th amino acid position is mutated to a 
phenylalanine (V617F). This mutation allows for constitutive activation of JAK2 kinase 
activity, which drives unregulated cell proliferation[48]. Possibly the most famous 
example of tyrosine kinase involvement in cancer progression is the fusion protein BCR-
ABL, produced by the chromosomal translocation of the breakpoint cluster region gene 
on chromosome 22 with the c-Abl tyrosine kinase on chromosome 9. The resulting 
chromosome is known as the Philadelphia Chromosome, and is found in 95% of all 
chronic myelogenous leukemia patients. The resulting fusion protein replaces exon 1 
from the c-Abl gene with the BCR gene, resulting in a constitutively active form of c-Abl. 
The BCR-ABL oncoprotein is then free to drive unregulated cell proliferation through 
activation of the RAS/MAPK, JAK2, PI3K, and CRKL pathways[13, 15-17, 19, 46, 49-51]. 
The ability of tyrosine kinases to disrupt many signaling networks at once makes them 
prime candidates for pharmacological inhibition, and the development of specific 
tyrosine kinase inhibitors marked a turning point in the ability of physicians to treat 







1.1.6 Chronic Myelogenous Leukemia Pathology 
Chronic Myelogenous Leukemia (CML) is a hematopoietic cancer caused by the 
formation of the Philadelphia Chromosome, a reciprocal translocation of the 3’ end of 
the gene encoding the ABL1 tyrosine kinase on chromosome 9, and the 5’ region of the 
breakpoint cluster region gene (BCR) chromosome 22, resulting in the BCR-ABL 
oncogene. The protein encoded by BCR-ABL is a constitutively active 210 kDa tyrosine 
kinase that regulates cell growth and differentiation, leading to uncontrolled cell 
proliferation by deregulating downstream signaling pathways[19, 46, 52]. The structure 
of the fusion protein lends insight into its constitutive nature. While the exon encoding 
the tyrosine kinase activity of ABL remains intact, the loss of an N-terminal 
myristoylation site removes an ABL autoinhibition site, resulting in increased kinase 
activity and unregulated propagation of downstream cell proliferation signals. Antisense 
oligonucleotides and knockout mouse models have demonstrated that BCR-ABL is a 
critical mutation on the path to develop CML, and thus represents an excellent target 
for innovative treatment strategies[53].  
 
The BCR-ABL fusion protein drives oncogenesis through multiple prominent signaling 
pathways. BCR-ABL activates the JAK/STAT pathway through activation of STAT5, a 
transcription factor necessary for CML development. STAT5 is a known substrate of 
JAK2, and knockout of STAT5 prior to BCR-ABL mediated CML induction prevented the 






the development and maintenance of CML, suggesting BCR-ABL is capable of activating 
STAT5 directly[50]. BCR-ABL also activates the Phosphoinositide 3-Kinase (PI3K) pathway 
through the activation of GRB2/GAB2 and CBL adaptor proteins, and pharmacological 
inhibition of PI3K signaling incudes apoptosis in primary CML cells[54]. However, BCR-
ABL is perhaps most commonly associated with the activation of Src-family kinases, 
kinases prominently involved in cell growth, differentiation, and motility. The SRC-family 
kinases HCK and LYN are strongly activated in the presence of BCR-ABL and along with 
FYN, another SRC-family kinase, are required for BCR-ABL mediated CML induction[42, 
55-58].  
BCR-ABL-mediated CML progression is not mechanistically limited to deregulated cell 
proliferation, but BCR-ABL also inactivates apoptosis pathways in a two-pronged 
manner. BCR-ABL mediated STAT5 regulation increases the expression of BCL-XL and 
BCL-2, anti-apoptotic genes that inhibit apoptosis by inhibiting cytochrome C release 
from the mitochondria, preventing caspase activation and thus inhibiting apoptosis[15].  
 Constitutively active BCR-ABL also activates the PI3K/AKT pathway, which 
phosphorylates the pro-apoptotic BCL2-associated Death promoter (BAD), promoting 
it’s association with 14-3-3 scaffolding proteins, sequestering BAD in the cytoplasm and 
preventing BAD from activating pro-apoptotic genes in the nucleus[54, 59, 60]. 
The progression of CML occurs in three phases. Most patients are diagnosed in the 






quiescent population of hematopoietic stem cells, termed Leukemic Stem Cells (LSCs), 
lies dormant in the bone marrow. Although it is yet unknown what molecular events 
lead quiescent cells to gain self-renewal capabilities and begin proliferating 
uncontrollably, CML can then progress through an accelerated phase (CML-AP), or 
directly to blast phase (CML-BP)[52, 61]. CML-AP is defined as the presence of any of the 
following symptoms: 10-19% myeloblasts present in the blood or bone marrow, platelet 
count <100,000 related to therapy, platelet count >1,000,000 and unresponsive to 
therapy, >20% basophils in the blood or bone marrow, cytogentic evolution unrelated to 
the presence of the Philadelphia Chromosome, increased splenogamy or white blood 
cell count and unresponsiveness to therapy. Accelerated phase signals an imminent 
progression to blast-phase, and an increased likelihood of drug resistance. Blast phase is 
characterized by rapid cell proliferation brought on by inhibition of tumor suppressor 
proteins, genomic instability, and shortened telomeres, resulting in >20% myeloblasts or 
lymphoblasts in the blood or bone marrow, large clusters of blasts in the biopsy, and the 
development of chloroma (a solid focus of tumor outside the bone marrow). Once a 
patient reaches blast phase, prognosis is bleak and the patient generally has a short 
time to live. It is critical to diagnose and treat CML patients before blast phase is 







1.1.7 Treatment of CML Using Tyrosine Kinase Inhibitors (TKIs) 
Prior to the introduction of imatinib, CML was treated with a combination of cytarabine 
and interferon-α therapy, or radiation therapy followed by allogenic stem cell 
transplantation (the transfer of stem cells from a healthy donor to the patient after 
radiation or chemotherapy). These treatment options were moderately effective, with 
the median 8-year survival rate between 42-65% from 1983-2000[64].  
The introduction of imatinib mesylate (Gleevec®) changed everything. Imatinib inhibits 
BCR-ABL by binding its kinase domain and trapping BCR-ABL in an inactive conformation, 
leading to its degradation and subsequent apoptosis of the cell. With a 7-year overall 
survival rate of 86% and an event free survival rate of 81%, imatinib was a huge success, 
and demonstrated that small molecule ATP-competitive inhibitors could be highly 
effective cancer treatments. Since then, TKIs have been approved for BTK, ALK, VEGFR, 
FGFR, KIT, SRC-family kinase, JAK, among other targets, however none have been as 
successful as imatinib. For many CML patients, a daily dose of imatinib transformed a 
deadly disease into a manageable condition, as BCR-ABL is the product of a fusion gene 
found only in cancer cells making it a highly specific target for a small molecule inhibitor. 
However, approximately 4% of CML patients are intrinsically resistant to imatinib, and 







Over 100 BCR-ABL point mutations have been identified, accounting for approximately 
70% of acquired resistance to imatinib[65]. Many of these mutations prevent the 
binding of imatinib in the ATP-binding pocket of BCR-ABL, leading to imatinib resistance. 
Second-generation BCR-ABL TKIs nilotinib and dasatinib have been developed which 
inhibit BCR-ABL even in the presence of several kinase domain mutations conferring 
resistance to imatinib, but resistance to both second-generation TKIs has been 
reported[66]. 
 
1.2 Imatinib, Nilotinib, and Dasatinib 
1.2.1 Imatinib 
Imatinib, originally termed STI571, is a methylpiperazine derivative that was developed 
by Novartis in the early 1990’s. In collaboration with Dr. Brian Druker, imatinib entered 
clinical trials and demonstrated remarkable efficacy in inducing apoptosis in CML cells. 
Imatinib works by outcompeting ATP to bind the ATP-binding pocket of BCR-ABL when 
in an inactive conformation, inhibiting its catalytic activity and driving apoptosis by 
inhibiting downstream signaling pathways necessary for cell proliferation. Imatinib 
inhibits BCR-ABL with high specificity, targeting only c-KIT and PDGFRα and PDGFRβ[67]. 
Because BCR-ABL is present in almost all CML cells, imatinib is an ideal treatment option 
for patients with CML. In June 1998, Dr. Brian Druker and colleagues initiated a phase I 
clinical trial in collaboration with Novartis deemed International Randomized Study of 






human patients who had failed interferon-α therapy. The results were striking. At 18 
months, the rates of Complete Cytogenic Response (CCyR, defined as 0% Ph+ cells) were 
76% in the imatinib group compared to only 15% in the group treated with a 
combination of interferon-α and cytarabine; at 60 months 97% of patients treated with 
imatinib achieved a CCyR[68]. At 18 months 100% of patients who achieved a Major 
Molecular Response (MMR; defined as a reduction in levels of BCR-ABL transcript to ≤ 
0.1% of the average level of BCR-ABL transcript in 30 untreated CP-CML patients) 
remained in chronic phase, not progressing to accelerated phase or blast phase. Despite 
the success of imatinib, 15-25% of patients are either intrinsically resistant to imatinib or 
acquire resistance over time. BCR-ABL kinase domain mutations are a common 
mechanism conferring resistance to imatinib. Over 50 kinase domain mutations have 
been identified, many of which prevent the binding of imatinib to the kinase 
domain[69]. To combat imatinib resistance second-generation tyrosine kinase inhibitors 
have been developed, which inhibit several variants of mutant BCR-ABL.  
 
1.2.2 Nilotinib 
Nilotinib is a second-generation BCR-ABL inhibitor that inhibits most BCR-ABL mutants 
with the exception of the T315I, Y253H, E255V/K, and F359V mutations, which confer 
moderate resistance to imatinib. Nilotinib is more selective than imatinib, and binds 
BCR-ABL in imatinib-sensitive CML 20-50 times more tightly than imatinib, and 3-7 times 






resistant patients, 46% of patients achieved a CCyR, and 56% achieved a MMR. At 24 
months there was an 87% overall survival rate, with a 64% event-free survival 
observed[70, 72]. As with imatinib, patients eventually become resistant to nilotinib, 
and there are limited options to combat nilotinib resistance[73].  
 
1.2.3 Dasatinib 
Dasatinib is an ATP competitive TKI with dual activity against both BCR-ABL and SRC- 
family kinases, specifically SRC, LCK, LYN, YES, FYN, and FRK. Dasatinib inhibits BCR-ABL 
more potently than nilotinib or imatinib and its activity against the SRC- family kinases, 
which have been implicated in TKI resistance, make it an advantageous treatment 
option for patients resistant to both imatinib and nilotinib[74-76]. In a phase II clinical 
trial of imatinib-resistant or imatinib-intolerant CML patients, dasatinib induced a CCyR 
in 53% of patients at 24 months[77]. Although dasatinib inhibits BCR-ABL more potently 
than nilotinib and imatinib, it does not effectively inhibit BCR-ABL containing the T315I, 
E255K/G, F317L, and Q252H mutations, and dasatinib is associated with the 
development of further mutations in the kinase domain, which may result in CML 
resistance to all currently FDA-approved TKIs[13, 74-76, 78-80]. Despite the success of 
first- and second-generation TKIs, there is clearly a need to develop third-generation 
TKIs that effectively inhibit TKI-resistant BCR-ABL mutations, and explore alternative 






1.2.4 Next-Generation CML Treatment 
There is an unmet need to effectively inhibit BCR-ABL mutants resistant to first-and 
second-generation TKIs. The most notorious mutation commonly found in patients 
resistant to imatinib, nilotinib, and dasatinib is the T315I mutation, also known as the 
gatekeeper mutation. The T315I mutation is significant because it removes a critical 
oxygen residue necessary for first- and second-generation TKIs to bind to the kinase 
domain of BCR-ABL and effectively inhibit its kinase activity. Several experimental 
compounds have been proposed to meet this need, and are in varying stages of 
development.  
 
Ponatinib is a novel tyrosine kinase inhibitor that is designed to inhibit the BCR-ABL 
T315I mutation, and was approved to treat patients with CP-CML, AP-CML, or BP-CML, 
as well as Ph+ Acute Lymphoblastic Leukemia (Ph+ ALL) in the United States and 
countries residing in the European Union. A phase II study of ponatinib yielded major 
cytogenic response in over half of adults with CP-CML, and a major hematological 
response in 50% of adults with BP-CML, and 34% of patients with Ph+ ALL, regardless of 
the presence or absence of the T315I mutation[81]. However, serious side effects such 
as vascular occlusion, heart failure, and hepatotoxicity have been observed in patients 
treated with ponatinib. Although ponatinib is a promising therapeutic option for 
patients resistant to other TKIs, it remains to be seen if patients will develop resistance 






1.2.5 Acquired Resistance Due to Compensatory Signaling Pathway Activation 
A commonly cited mechanism of resistance to imatinib and nilotinib is the over-
activation of compensatory proliferative signaling pathways that allow CML cells to 
evade cell death.  BCR-ABL activates several prominent signaling pathways, such as the 
SRC- signaling pathway, which includes LYN, a member of the SRC-family kinases. 
Knockdown of LYN using antisense RNA has restored imatinib and nilotinib sensitivity in 
vitro[15, 58, 82], however, dasatinib inhibits SRC-family kinase activity and patients 
lacking the T315I mutation still develop resistance to dasatinib[83], suggesting that the 
SRC-family kinase signaling pathway is not the only pathway compensating for BCR-ABL 
inhibition. In fact, constitutive ERK2 activation has been identified as a mechanism of de 
novo resistance to imatinib[84], and PI3K/AKT activation has also been described as a 
mechanism underlying BCR-ABL independent acquired imatinib resistance[54]. The 
study of BCR-ABL independent compensatory signaling pathway activation represents a 
promising therapeutic avenue, as pharmacological inhibition of these signaling 
pathways could be an effective strategy to mitigate BCR-ABL independent TKI-resistance.  
 
1.2.6 Altered Expression of Drug Influx and Efflux Channels 
The success of BCR-ABL inhibition is dependent upon the intracellular concentration of 
the inhibitor, and alteration of the expression of influx and efflux pumps can affect the 
internalization and accumulation of small-molecule inhibitors. Several studies have 






and its translational product P-glycoprotein (PgP) in acquired resistance to imatinib. 
RNAi-mediated knockdown of PgP restored sensitivity to imatinib and increased 
intracellular concentrations of imatinib in K562 cells in-vitro, and pharmacological 
inhibition of PgP yielded similar results[85, 86]. In the other direction, other studies 
have demonstrated downregulation of influx pumps correlating with imatinib 
resistance. The best studied of these transporters is OCT1, an organic cation transporter 
responsible for transporting imatinib into the cell. Pharmacological inhibition of OCT1 
resulted in reduction of imatinib uptake in CML cells, but the results of the study did not 
establish reduced OCT1 expression as a direct cause of imatinib resistance[87]. 
Subsequent studies have linked low OCT1 expression with reduced response to imatinib 
compared to patients that achieved a CCyR at 10 months following the onset of imatinib 
therapy[88], and patients with low expression of OCT1 receiving high doses of imatinib 
had much better rates of CCyR, MMR, and PFS than those with low expression of OCT1 
receiving a standard dose of imatinib. Interestingly, patients with high expression of 
OCT1 responded to either dosage equally well. Taken together, the expression of drug 
influx and efflux transporters is a critical factor determining a patient’s sensitivity to TKI 
therapy. There are many factors contributing to TKI-resistance. In this thesis we describe 
the use of transcriptomics and proteomics to identify potential mechanisms mediating 







CHAPTER 2. IDENTIFICATION OF TRANSCRIPTOMIC DIFFERENCES BETWEEN WILD-
TYPE CML CELLS AND CML CELLS RESISTANT TO TYROSINE KINASE INHIBITORS  
2.1 Introduction 
Despite the success of frontline CML treatments such as imatinib, 15-25% of CML 
patients will eventually develop resistance to therapy. In many cases, the roots of 
resistance can be traced to mutations in the kinase domain of BCR-ABL, preventing 
imatinib from binding to the ATP-binding pocket and inhibiting the catalytic activity of 
the kinase. However, approximately 30% of patients that develop resistance to imatinib 
do not exhibit any mutations preventing imatinib binding. Various explanations for BCR-
ABL independent resistance have been proposed, such as the overexpression of BCR-
ABL[49], compensatory signaling pathway activation[15, 82, 84, 89], downregulation of 
influx pumps[90], and upregulation of efflux pumps[18], but further study is required to 
identify potential biomarkers of TKI-resistance and novel mechanisms of resistance. 
Every CML patient has a unique biological response to any chemotherapy, and it is 
currently impossible to predict which TKI will most effectively inhibit BCR-ABL activity in 
an individual patient. Further, the current gold standard to measure the efficacy of a TKI 
in a CML patient is to measure BCR-ABL transcript level approximately 90 days after the 
onset of treatment. A goal in the Parker lab is to design novel peptide substrates 






the ability of each TKI to inhibit kinase activity, physicians will be able to make a more 
informed decision regarding TKI treatments on a patient-by-patient basis. Evidence 
asuggests that a 50% reduction of BCR-ABL activity at 28 days is equally predictive of 
treatment efficacy as measurement of BCR-ABL transcript levels at 90 days[91], and the 
development of a reliable method to test treatment efficacy based on the measurement 
of BCR-ABL activity would potentially improve patient survival rate and reduce the cost 
of therapy.  
 
The Parker lab has developed a set of TKI-resistant CML cell lines based on the K562 
immortalized myeloid cell line containing the BCR-ABL fusion protein, with the goal of 
elucidating novel biomarkers of drug resistance. To our knowledge no study has 
examined a cell line model of acquired TKI-resistance using next-generation sequencing. 
Here we describe the use of RNA sequencing (RNA-seq) to profile the transcriptomic 
differences between the wild type K562 CML cell line, and cell lines with evolved 
resistance to the TKIs imatinib, nilotinib, and dasatinib. The goal of this study is to 
identify potential biomarkers of acquired resistance to TKI-treatment in vitro, that may 
be able to be used to monitor resistance development in patient cells and/or suggest 







2.2 RNA-seq Profile of TKI-resistant K562 Cells 
2.2.1 Materials and Methods 
Generation of TKI-resistant Cell Lines. Dr. Steven Ouellette generated cells. K562 cells 
were purchased from ATCC and grown in Isocove’s Modified Dulbecco’s Media (IMDM) 
supplemented with 10% Fetal Bovine Serum (FBS) and 0.1% penicillin/streptomycin 
antibiotics in a humidified atmosphere maintained at 37°C and 5% CO2. The cells were 
then divided into four groups, one treated with imatinib, one treated with nilotinib, and 
one treated with dasatinib, and one supplemented with 1:1,000 DMSO.  Over the course 
of 90 days, the cells were incubated with escalating doses of TKI and gradually acquired 
resistance to the TKI in which they were incubated. The resulting cell lines were termed 
K562-IR (which is maintained in IMDM supplemented with 1μM imatinib), K562-NR 
(which is maintained in IMDM supplemented with 10nM nilotinib), and K562-DR (which 
is maintained in IMDM supplemented with 1nM dasatinib). Each cell line was split into 
three 10 cm tissue culture plates and passaged twice. When the density of the cells 
reached ~7.5x105 cells/mL media the cells were harvested and total RNA was isolated 
using an RNEasy kit from Qiagen. The RNA was then submitted to the University of 
Minnesota Genomic Core for RNA-seq analysis on an Illumina HiSeq 2500 sequencer 
using rapid mode with 50 base pair reads, and a total of 10 million reads per lane.  
 
Differential Expression Testing. The resulting RNA-seq data were analyzed using the 






compute differential gene expression between conditions, the raw data were first 
groomed to remove adapter bases using FASTQ Groomer[92], and then aligned to the 
Human hg19 canonical reference genome using Tophat2[93]. Differential expression 
testing between the wild type K562 cells and K562-IR, K562-NR, and K562-DR cells, 
respectively, was computed using Cuffdiff, a transcript computation program available 
as a package through Cufflinks[94].  
 
Novel Fusion Transcript Detection. After the raw RNA-seq data were aligned to the 
Human hg19_canonical reference genome using Tophat2, novel fusion transcripts were 
detected using DeFuse, as software package used to detect fusion transcripts from 
paired-end RNA-seq data[95].  
 
Growth Inhibition Assay. K562, K562-IR, K562-NR, and K562-DR cells were transfected 
with 100nM of AXL siRNA (Cell Signaling #6263), 100nM ACP5 siRNA (Life Technologies 
#10032), or 100nM of CYP2S1 siRNA (Life Technologies #113728), respectively using a 
Neon Transfection system (Thermo Fisher Scientific) and incubated at 37°C in a 5% CO2 
humidified atmosphere. The cells were seeded at 10,000 cells per well in 96-well plates 
and dosed with the indicated TKI concentrations or vehicle control (0.1% DMSO) 24 
hours after transfection. The remaining cells were reserved for Western blot analysis. 






Following incubation, XTT reagent (ATCC) was added according to manufacturer’s 
protocol and plates were incubated at 37°C in a 5% CO2 humidified atmosphere for 3 
hours. Specific absorbance was read on a Biotek Synergy4 plate reader at 475 nm and 
non-specific absorbance read at 660 nm. Absorbance values at 660 nm were subtracted 
from 475 nm absorbance values before further data processing. To generate IC50 
values, data were plotted in GraphPad Prism and curves were fit using non-linear four-
parameter slope.  
 
Western Blot Analysis. Cells were treated as described and pelleted by centrifugation. 
Media was removed, and cells were washed in ice cold PBS. After washing, lysis buffer 
(PhosphoSafe Extraction Buffer supplemented with 4 mM EDTA and Complete protease 
inhibitor (Roche)) was added to the cell pellet and cells were incubated on ice for 30 
minutes. Cell pellets were vortexed, then centrifuged at 4° C for 20 minutes to remove 
insoluble cellular debris and lysate was assayed for protein content. 100 μg of protein 
was mixed with Laemmli protein gel loading buffer (BioRad) and incubated at 95° C for 5 
minutes. Lysate were loaded onto a 10% Mini-Protean TGS gel 59 59 (BioRad) and 
separated at constant 150 V for 1 hour. Proteins were transferred to a PVDF membrane 
(Millipore) and blocked with 5% BSA in TBST (tris-buffered saline supplemented 
supplemented with 0.05% Tween-20). Primary antibodies (AXL (Cell Signaling, #8661), 
ACP5 (Sigma Aldrich SAB1401003), CYP2S1 (Novus Biologicals NBP2-32697,), GAPDH 






overnight at 4° C. Following 3 x 5 minute washes with TBST, the membrane was 
incubated with donkey anti-rabbit tagged with IRDye 800 or donkey anti-mouse tagged 
with IRDye 680(1:5000 in TBST) for 1 hours at room temperature. After 3 x 5 minute 
washes with TBST, the membrane was developed on a LICOR Odyssey infrared scanner. 
 
2.2.2 Analysis of RNA-seq Results 
2.2.3 Differential Expression Between K562 and K562-IR Cell Lines 
The use of next-generation sequencing has been a powerful research tool to identify 
difference in gene expression in a variety of pathologies and developmental stages[96-
98]. RNA-seq is a highly quantitative method to measure absolute transcript levels 
across samples without the need to normalize data to a set of standards, and the 
incredible sensitivity allows for a theoretical measurement of all transcripts present in a 
population of cells. We aimed to identify differences in transcription between wild type 
K562 cells and K562-IR cells in order to identify biomarkers for resistance, and 
potentially explain mechanisms of resistance to imatinib treatment. After analysis using 
Cuffdiff, we identified fifty-eight genes that were differentially expressed at a significant 








Table 1. K562-IR genes found to have significant (p>0.05) differential expression with 
respect to parental K562 cells determined by RNA-seq. Differential expression was 
analyzed using Cufflinks on the Galaxy platform. Fold change is expressed in terms of 
log2.   
Gene Fold Change (log2) p-value Function 
SIGLEC6 -4.37 1.00E-04 other 
FCGRT -3.292 5.00E-05 
transmembrane 
receptor 
PALM3 -3.184 5.00E-05 other 
RASGRP4 -2.967 5.00E-05 other 
CD33 -2.589 5.00E-05 other 
TLE2 -2.527 5.00E-05 
transcription 
regulator 
ZNF433 -2.288 5.00E-05 other 
B3GNT8 -1.78 2.25E-03 enzyme 
PALM -1.455 5.00E-05 other 
CD320 -1.344 5.00E-05 other 
NFIX -1.303 5.00E-05 
transcription 
regulator 
RAB3A -1.28 1.50E-04 enzyme 
C19orf51 -1.222 5.00E-05 other 
PPP1R14A -1.209 5.00E-05 phosphatase 
DLL3 -1.176 3.45E-03 other 
CD37 -1.17 5.00E-05 other 
CFD -1.17 5.00E-05 peptidase 
BRSK1 -1.151 2.00E-04 kinase 
AURKC -1.144 1.28E-02 kinase 
TUBB4A -1.137 5.00E-05 other 
TYROBP -1.071 6.10E-03 
transmembrane 
receptor 
FUZ -1.022 8.60E-03 other 









Table 1 Continued. 
EHD2 1.035 5.00E-05 other 
ZNF626 1.039 3.50E-04 other 
PRX 1.047 5.00E-05 other 
EXOC3L2 1.08 5.00E-05 other 
SERTAD1 1.084 5.00E-05 
transcription 
regulator 
ZNF134 1.094 5.00E-05 
transcription 
regulator 
HCN2 1.097 5.00E-05 ion channel 
BBC3 1.128 5.00E-05 other 
CNN1 1.192 5.00E-05 other 
VSIG10L 1.309 5.00E-05 other 
KCNC3 1.324 5.00E-05 ion channel 
KLK1 1.357 5.00E-05 peptidase 
GDF15 1.457 5.00E-05 growth factor 
KCNN4 1.494 5.00E-05 ion channel 
RRAS 1.534 5.00E-05 enzyme 
ZNF91 1.631 5.00E-05 
transcription 
regulator 
TNFSF9 1.653 5.00E-05 cytokine 
ZNF347 1.674 5.00E-05 other 
ZNF211 1.711 5.00E-05 
transcription 
regulator 
SCN1B 1.734 5.00E-05 ion channel 
KLK13 1.793 5.00E-05 peptidase 
ZNF551 1.835 5.00E-05 other 
GP6 1.876 5.00E-05 
transmembrane 
receptor 
F2RL3 1.935 5.00E-05 
G-protein coupled 
receptor 
PPP1R13L 1.941 5.00E-05 
transcription 
regulator 
ZSCAN18 1.953 5.00E-05 other 
CLEC11A 2.175 5.00E-05 growth factor 






Table 1 Continued. 
CYP2S1 2.616 5.00E-05 enzyme 
SYT3 2.652 5.00E-05 transporter 
AXL 2.784 5.00E-05 kinase 
ZNF85 2.838 1.00E-04 
transcription 
regulator 
LRRC4B 3.301 5.00E-05 other 
ACP5 3.472 5.00E-05 phosphatase 
HKR1 3.767 5.00E-05 Other 
 
The initial analysis of differential expression yielded some interesting results. Many of 
the genes displaying a high level of differential expression were transcription factors or 
encoded for transmembrane transport proteins, and several canonical signaling 
molecules were absent, such as members of the SRC-family kinases or AKT pathway. It is 
also noteworthy that many of the genes identified have not been described in cancer 
models, which may reflect their status as passenger genes, not directly responsible for 
any mechanism of resistance. Further study is warranted to determine what, if any, 
influence these genes have in imatinib resistance.  
 
Several genes significantly differentially expressed genes are interesting candidates for 
further research. The most downregulated gene was SIGLEC6, a transmembrane 
receptor responsible for binding leptin. Two studies have associated increased SIGLEC6 






trophoblastic disease and mucosa-associated lymphoid tissue lymphoma[99, 100], 
however we report a significant reduction in the transcription of SIGLEC6 in imatinib-
resistant K562 cells. BRSK1  (-1.151 log2 fold change) a serine/threonine kinase involved 
in cell cycle regulation and the DNA damage response that has not been examined in 
any human leukemia models. Currently, the only description of BRSK1 expression levels 
in human cancer indicates that BRSK1 functions as a tumor suppressor in human breast 
cancer, and low levels of BRSK1 correlate with poor prognosis[101].  
Aurora C (ARKC) has not been thoroughly investigated in human cancers, despite being a 
member of the Aurora Kinase family, of which Aurora A and Aurora B are known to be 
involved in oncogenesis. The few studies that have investigated ARKC’s role in cancer 
have concluded that increased ARKC activity drives cancer progression[102, 103], 
however we observed a downregulation (-1.144 log2 fold change) of ARKC transcription.  
 
The most highly upregulated gene, HKR1 (3.767 log2 fold change), is a Krüppel-type ZNF 
gene that has only been investigated in one study, which showed that exposure to 
cisplatin induced the transcription of HKR1[104]. Lastly, AXL is a receptor tyrosine kinase 
that has been implicated in imatinib resistance. Previous studies have demonstrated 
that AXL overexpression is associated with imatinib resistance through a scaffold 






of our RNA-seq experiment demonstrated a 2.784 log2 fold change for AXL transcripts, 
which supports previous reports.  
 
2.3.2 Differential Expression Between K562 and K562-NR Cell Lines 
Nilotinib is another frontline tyrosine kinase inhibitor commonly prescribed to treat 
patients with Ph+ CML. Nilotinib inhibits BCR-ABL 10-30 times more potently than 
imatinib does, and also inhibits c-KIT, LCK, EPHA3, EPHA8, DDR1, DDR2, PDGFRB, 
MAPK11, and ZAK. Patients who have acquired resistance to imatinib can achieve some 
level of response to nilotinib, as a study found that 39% of patients with BP-CML 
achieved a hematological response and 27% had a cytogenic response to nilotinib after 
failing imatinib treatment[70]. This is possibly due to the fact that nilotinib inhibits all 
BCR-ABL kinase domain mutants except T315I, Y253H, E255K/V, and F359C/V[16, 70, 
71], however, in a study of imatinib-resistance CML patients 23% of patients treated 
with nilotinib developed resistance within two years[14]. Interestingly, patients treated 
with nilotinib developed BCR-ABL mutations at a reduced rate compared with patients 
treated with imatinib[107], which suggests the possibility that resistance to nilotinib is 
dependent upon mechanisms other than target mutation, such as compensatory 
signaling pathway activation, BCR-ABL upregulation, a reduction in influx transport 






differential gene expression between the parental K562 cell line and the K562-NR cell 
line, which has evolved resistance to nilotinib. The results are shown in Table 2 below.  
 
Table 2. K562-NR genes found to have significant (p>0.05) differential expression with 
respect to parental K562 cells determined by RNA-seq. Differential expression was 
analyzed using Cufflinks on the Galaxy platform. Fold change is expressed in terms of 
log2.   
Gene Fold Change (log2) p-value Function 
BLOC1S3 -3.109 5.00E-05 other 
ZNF257 -2.888 5.00E-05 other 
EID2 -2.493 5.00E-05 other 
ZNF429 -2.486 5.00E-05 other 
TUBB4A -2.422 5.00E-05 other 
NFIX -2.261 5.00E-05 transcription regulator 
ZFP30 -2.216 5.00E-05 other 
FOXA3 -2.12 5.00E-05 transcription regulator 
HAUS8 -2.067 5.00E-05 other 
ZNF433 -1.942 1.50E-04 other 
C3 -1.876 5.00E-05 peptidase 
GEMIN7 -1.856 5.00E-05 other 
NLRP2 -1.832 5.00E-05 other 
CCDC8 -1.753 5.00E-05 other 
SCAMP4 -1.752 5.00E-05 other 
ASF1B -1.653 5.00E-05 other 
ZNF607 -1.65 5.00E-05 other 
ARRDC2 -1.636 5.00E-05 other 
ZNF283 -1.619 3.00E-04 other 
PALM3 -1.619 5.00E-05 other 
SIGLEC6 -1.618 3.00E-04 other 






Table 2 Continued. 
RASGRP4 -1.608 5.00E-05 other 
CCDC97 -1.601 5.00E-05 other 
KISS1R -1.596 1.80E-03 G-protein coupled receptor 
ZNF550 -1.595 3.90E-03 other 
ZNF616 -1.58 5.00E-05 other 
ZNF816 -1.571 5.00E-05 other 
SPHK2 -1.495 5.00E-05 kinase 
VAV1 -1.477 5.00E-05 transcription regulator 
ZNF788 -1.465 5.00E-05 other 
ZNF30 -1.46 5.00E-05 other 
ZNF324 -1.451 5.00E-05 other 
EMR2 -1.442 5.00E-05 other 
SIX5 -1.442 5.00E-05 transcription regulator 
ZNF175 -1.44 5.00E-05 transcription regulator 
ZNF8 -1.426 5.00E-05 other 
FCGRT -1.406 1.50E-04 transmembrane receptor 
ZNF253 -1.387 2.00E-04 transcription regulator 
SLC25A41 -1.38 2.75E-03 other 
MIER2 -1.361 5.00E-05 other 
LRG1 -1.334 5.00E-05 other 
ZNF14 -1.322 5.00E-05 transcription regulator 
ZNF567 -1.316 5.00E-05 other 
MOB3A -1.302 5.00E-05 other 
EPOR -1.295 5.00E-05 transmembrane receptor 
LRRC8E -1.288 5.00E-05 other 
ZNF614 -1.279 5.00E-05 other 
PALM -1.276 5.00E-05 other 
ZNF761 -1.26 5.00E-05 other 
CD3EAP -1.239 5.00E-05 other 
TBXA2R -1.234 5.00E-05 G-protein coupled receptor 
PPAN -1.211 5.00E-05 other 
SCAF1 -1.2 5.00E-05 other 
DPY19L3 -1.198 5.00E-05 other 
ZNF181 -1.188 4.00E-04 other 






Table 2 Continued.  
PRR12 -1.162 5.00E-05 other 
ITPKC -1.16 5.00E-05 kinase 
NFIX -1.152 5.00E-05 transcription regulator 
LDLR -1.139 5.00E-05 transporter 
PPP6R1 -1.139 5.00E-05 other 
ZNF320 -1.123 5.00E-05 other 
CD37 -1.116 2.90E-03 other 
ZNF507 -1.109 5.00E-05 other 
NUP62 -1.094 5.00E-05 transporter 
NR1H2 -1.081 5.00E-05 
ligand-dependent nuclear 
receptor 
TICAM1 -1.073 5.00E-05 other 
RASIP1 -1.069 5.00E-05 other 
PIP5K1C -1.059 5.00E-05 kinase 
MYADM -1.049 5.00E-05 other 
KRI1 -1.023 5.00E-05 other 
RDH13 -1.01 5.00E-05 enzyme 
PAK4 1.01 5.00E-05 kinase 
PLAUR 1.023 5.00E-05 transmembrane receptor 
ZNF358 1.025 5.00E-05 other 
UBE2S 1.026 5.00E-05 enzyme 
CNN1 1.027 5.00E-05 other 
TEAD2 1.036 5.00E-05 transcription regulator 
FLT3LG 1.044 6.00E-04 other 
ETHE1 1.054 5.00E-05 enzyme 
KLF16 1.059 5.00E-05 other 
GLTSCR2 1.061 5.00E-05 other 
PNPLA6 1.073 5.00E-05 other 
RPS15 1.076 5.00E-05 other 
KDELR1 1.081 5.00E-05 transporter 
KLK1 1.106 5.00E-05 peptidase 
HOMER3 1.116 5.00E-05 other 
HRC 1.127 5.00E-05 other 
DOCK6 1.146 5.00E-05 other 






Table 2 Continued.  
RPL28 1.159 5.00E-05 other 
SCN1B 1.19 2.20E-03 ion channel 
RPL13A 1.192 5.00E-05 other 
AP2S1 1.21 5.00E-05 transporter 
JUND 1.235 5.00E-05 transcription regulator 
ECH1 1.301 5.00E-05 enzyme 
DBP 1.338 5.00E-05 transcription regulator 
PRX 1.348 5.00E-05 other 
PEPD 1.355 5.00E-05 peptidase 
LRRC4B 1.385 5.00E-05 other 
C19orf79 1.404 3.00E-03 other 
KCNN4 1.429 5.00E-05 ion channel 
CERS1 1.43 5.00E-05 enzyme 
ARHGAP33 1.482 5.00E-05 transporter 
PPP1R13L 1.559 5.00E-05 transcription regulator 
ZNF296 1.588 3.00E-04 other 
TNFSF9 1.682 5.00E-05 cytokine 
A1BG 1.764 5.00E-05 other 
BBC3 1.781 5.00E-05 other 
VSIG10L 1.815 5.00E-05 other 
RRAS 2.01 5.00E-05 enzyme 
CLEC11A 2.08 5.00E-05 growth factor 
GDF15 2.083 5.00E-05 growth factor 
APOC1 2.086 5.00E-05 transporter 
APOE 2.208 5.00E-05 transporter 
CYP2S1 2.246 5.00E-05 enzyme 
TNNI3 2.251 5.00E-05 transporter 
KLK13 2.437 5.00E-05 peptidase 
ZNF85 2.464 3.50E-04 transcription regulator 
SERTAD1 2.591 5.00E-05 transcription regulator 
AXL 2.679 5.00E-05 kinase 
PPP1R15A 2.768 5.00E-05 other 
GADD45B 3.091 1.10E-03 other 
ACP5 4.7 5.00E-05 phosphatase 






The RNA-seq results identified 126 genes that were significantly differentially expressed 
in the K562-NR cell line as compared to the K562 parental cell line. Interestingly, many 
of the genes that are the most significantly differentially expressed have not been 
characterized in leukemia, or other human cancers. BLOC1S3 encodes for a protein in 
the BLOC1 multi-protein complex, which regulates biogenesis of specific organelles in 
the endosomal-lysosomal system. Despite finding that BLOC1S3 has a log2 fold change 
of -3.109 in K562-NR cells as compared to K562 cells, no role in any human cancer has 
been described as of yet.  
 
One very interesting finding is the downregulation of NFIX, a transcription factor critical 
to the regulation of differentiation in the hematopoietic system. The loss of NFIX 
perturbed normal gene expression in myeloid and lymphoid cells in-vivo, and NFIX has 
been demonstrated to interact with c-JUN in viral disease models[108, 109]. 
Furthermore, NFIX is a known target of miR-659-3p, a biomarker of improved 
progression-free survival in metastatic melanoma[110]. Taken together with our RNA-
seq results, these studies suggest NFIX is an interesting candidate for further study of its 
role in nilotinib-resistant CML.  
 
SERTAD1 is upregulated at a log2 fold change of 2.591 in K562-NR cells compared to 
K562 cells. SERTAD1 is a transcription factor interacting with the PHD-bromodomain-1, 






D1/CDK4 resistant to the inhibitory effects of CDKN2A/p16INK4A[111, 112]. 
Furthermore, SERTAD1 has been shown to inhibit the tumor suppressor protein PTEN in 
breast cancer cells, leading to cell survival and increased tumorigenesis by activating the 
PI3K/AKT cell proliferation pathway[113]. The significant upregulation in K562-NR cells 
and previously established role in tumorigenesis makes SERTAD1 a potential target for 
further studies examining the roots of nilotinib resistance in CML. 
 
Another interesting set of genes that are significantly upregulated in K562-NR cells 
compared to K562 cells are APOE and APOC1, upregulated at a log2 fold change of 2.208 
and 2.086, respectively. Members of the apolipoprotein family, APOE and APOC1 are 
primarily involved with binding, internalization, and catabolism of lipoproteins, and 
APOC1 has been implicated in the progression of pancreatic cancer[114], while 
increased expression of APOE is a biomarker of aggressive acute lymphoblastic leukemia 
and has been correlated with short progression-free survival in metastatic colorectal 
cancer[115, 116]. APOC1 is also overexpressed in gastric cancer, and treatment with the 
histone deacetylase inhibitor vorinostat dramatically reduced the transcription of 
APOC1 and induced cell death[117]. Many recent studies have investigated the use of 
vorinostat in acute myeloid leukemia, and it may be beneficial to examine its effects in 







Given the large raw data output from RNA-seq experiments, it can be difficult to 
determine if perturbation of a particular pathway may underlie resistance to TKI 
treatment. We used Ingenuity Pathway Analysis software (Qiagen) to establish 
pathways affected by nilotinib resistance, and found that the Eukaryotic Initiation Factor 
2 pathway (EIF2) had a significant p-value (p=3.02-3) and a z-score of 2. This indicates 
that the differential expression of the genes involved in this pathway predict that the 
EIF2 pathway will be activated in K562-NR cells. The genes differentially expressed in 
K562-NR cells that predict the activation of the EIF2 pathway are RPL18A, RRAS, RPL28, 
PPP1R15A, RPS15, and RPL13A, all of which are upregulated in K562-NR cells compared 
to K562 cells. Phosphorylation of EIF2 subunits inhibits protein synthesis and leads to 
apoptosis, but interestingly, PPP1R15A binds to PP1 and activates the EIF2 pathway 
through dephosphorylation of EIF2-α[117]. Treatment of T-cell Leukemia (T-ALL) with 
pegylated-human-arginase I (peg-Arg-I) induced decreased expression of PPP1R15A and 
subsequent dephosphorylation of EIF2, resulting in apoptosis in T-ALL bearing 
mice[118]. Targeting the EIF2 pathway may be a viable therapeutic option for patients 
resistant to nilotinib. 
 
2.2.3 Differential Expression Between K562 and K562-DR Cell Lines 
Dasatinib is a second-generation dual BCR-ABL/SRC inhibitor that binds approximately 
325 times more tightly to wild type BCR-ABL than imatinib, and can overcome some of 






compensatory activation confers TKI-resistance. The results of the DASISION (Dasatinib 
versus Imatinib Study in Treatment-Naive CML-CP) clinical trials were recently 
published, in which 65% of the dasatinib-treated patients required BCR-ABL mutational 
analysis due to treatment issues (no cCCyR within 12 months; no MMR within 12 
months; fivefold increase in BCR-ABL1 transcript levels with loss of MMR; loss of CCyR), 
and surprisingly, only 9% of dasatinib-treated patients had developed BCR-ABL 
mutations[17]. It seems clear that further analysis of BCR-ABL independent dasatinib 
resistance is warranted. We developed a dasatinib-resistant K562 cell line (K562-DR) by 
culturing K562 cells in escalating concentrations of dasatinib, and performed RNA-seq 
on K562-DR cells to compare the transcriptomes of K562-DR cells with the parental K562 
cells to identify potential mechanisms of resistance, and identify novel biomarkers of 
dasatinib resistance. The significantly differentially expressed genes in K562-DR cells as 
compared to K562 cells are shown in Table 3 below. 
 
 
Table 3. K562-DR genes found to have significant (p>0.05) differential expression with 
respect to parental K562 cells determined by RNA-seq. Differential expression was 
analyzed using Cufflinks on the Galaxy platform. Fold change is expressed in terms of 







Gene Fold Change (log2) p-value Function 
ZNF433 -3.861 2.70E-03 other 
RASGRP4 -2.08 5.00E-05 other 
ZNF257 -1.841 5.00E-05 other 
ZNF93 -1.812 5.00E-05 transcription regulator 
CD33 -1.725 5.00E-05 other 
MYO1F -1.435 5.00E-05 other 
PALM3 -1.435 5.00E-05 other 
ZNF559 -1.297 5.00E-05 other 
B3GNT8 -1.279 3.75E-03 enzyme 
CD320 -1.184 5.00E-05 other 
TSKS -1.165 5.00E-04 kinase 
NFIX -1.083 5.00E-05 transcription regulator 
CALR -1.07 5.00E-05 transcription regulator 
DUS3L -1.068 5.00E-05 other 
C3 -1.024 5.00E-05 peptidase 
ZNF776 1.011 5.00E-05 other 
F2RL3 1.031 5.00E-05 
G-protein coupled 
receptor 
EXOC3L2 1.036 5.00E-05 other 
LINC00085 1.05 5.00E-05 other 
SIPA1L3 1.085 5.00E-05 other 
ZNF91 1.088 5.00E-05 transcription regulator 
ZNF600 1.178 5.00E-05 other 
ZNF432 1.21 2.00E-04 other 
VSIG10L 1.248 5.00E-05 other 
CLEC11A 1.252 5.00E-05 growth factor 
KLF1 1.26 5.00E-05 transcription regulator 
ZNF347 1.261 5.00E-05 other 
ZNF253 1.397 5.00E-05 transcription regulator 
ZNF813 1.626 5.00E-05 other 
ZNF551 1.772 5.00E-05 other 
ZNF211 1.783 5.00E-05 transcription regulator 
KLK1 1.84 5.00E-05 peptidase 
KCNC3 1.861 5.00E-05 ion channel 






Table 3 Continued. 
ZNF134 1.921 5.00E-05 transcription regulator 
PPAP2C 2.012 5.00E-05 phosphatase 
ZNF671 2.101 5.00E-05 other 
PPP1R13L 2.138 5.00E-05 transcription regulator 
KCNN4 2.157 5.00E-05 ion channel 
SYT3 2.181 1.00E-04 transporter 
ZSCAN18 2.305 5.00E-05 other 
RPL18A 2.441 5.00E-05 other 
AURKC 2.45 5.00E-05 kinase 
TNNI3 2.457 5.00E-05 transporter 
CYP2S1 2.475 5.00E-05 enzyme 
HKR1 2.584 7.00E-04 other 
AXL 2.766 5.00E-05 kinase 
ACP5 2.907 5.00E-05 phosphatase 
ZNF85 2.973 2.00E-04 transcription regulator 
LRRC4B 3.057 5.00E-05 other 
 
Dasatinib inhibits SRC-family kinases in addition to BCR-ABL, so one would expect a 
different set of genes to be differentially expressed in K562-DR cells as compared to 
K562-IR and K562-NR cells. As with the K562-IR and K562-NR cell lines, many members 
of the zinc-finger family (ZNF) of transcription factors are differentially expressed, 
however the vast majority of ZNF proteins are uncharacterized, and understanding their 
function in the context of TKI resistance would be a difficult task.  
 
Ras guanyl nucleotide releasing protein 4 (RASGRP4) is a guanyl nucleotide exchange 






proliferation[119]. Interestingly, RASGRP4 is highly expressed in myeloid cells, and high 
expression of RASGRP4 has been observed in acute myeloid leukemia[120, 121]. 
Interestingly, the results of our RNA-seq experiment show RASGRP4 has a (log2 fold 
change of -2.080 in K562-DR cells compared to K562 cells, potentially indicating that the 
mechanism of dasatinib resistance is independent of RAS activation. Further 
experimentation is needed to confirm our results, but RAS activation likely does not 
contribute to dasatinib resistance.  
 
Another interesting finding from our K562-DR RNA-seq experiment is the 
downregulation of B3GNT8 (log2 fold change of -1.279) compared to K562 cells. B3GNT8 
is an enzyme that regulates the elongation of specific branch structures of 
multiantennary N-glycans, and is involved with the biosynthesis of N-glycan precursor 
proteins. The results of our RNA-seq experiment demonstrated a significant 
downregulation of B3GNT8, but several other studies have demonstrated B3GNT8 plays 
a significant role in cancer progression. B3GNT8 silencing reduces cell proliferation, 
migration, and metastasis in human glioma cells[122], and human laryngeal carcinoma 
cells[123]. Even more interesting is the fact that B3GNT8 was overexpressed in 
multidrug-resistant K562 cells, and knockdown of B3GNT8 increased sensitivity to 
adriamycin[124]. B3GNT8 has been suggested to increase resistance to chemotherapy 
by activating TGF-β signaling, which increases cell proliferation and resistance to 






compared to K562 cells. This does not exclude the possibility that TGF-β activity is 
increased, however it is not possible to draw that conclusion based on transcriptomic 
data alone.  
 
Analysis of the RNA-seq data comparing the genes expressed in our K562-DR cell line 
and K562 cells shows many of the significantly differentially expressed genes are 
upregulated in K562-DR cells despite having been reported to be downregulated in 
other cancers, and vice versa. The most differentially expressed gene in our RNA-seq 
results is LRRC4B, a protein regulating neurite outgrowth and dendrtitic segmentation in 
the developing brain. LRRC4B has been identified as a tumor suppressor in glioma 
carcinoma[36, 125], as overexpression of LRRC4 inhibited glioma tumorigenesis and 
induced apoptosis. We report an upregulation of LRRC4B (log2 fold change of 3.057), 
which conflicts with reports that LRRC4B is a tumor suppressor. LRRC4B may be a 
passenger gene, and its upregulation may have no effect on TKI-resistance.  
 
One possible explanation for dasatinib resistance is the upregulation of Aurora Kinase C 
(AURKC), which was found to have a log2 fold change of 2.450. AURKC is a 
serine/threonine kinase that forms a complex with Aurora B kinase and plays a role in 
organizing microtubules in relation to the centrosome during mitosis. Several Aurora A 






leukemias, and treatment of imatinib-resistant CML patients with the Aurora A inhibitor 
MLN8237 was shown to significantly increase the efficacy of nilotinib, suggesting Aurora 
A activity may contribute to imatinib resistance[126]. AURKC has been noted to be 
upregulated in prostate cancer, epithelial cancer, colorectal cancer, and thyroid 
cancer[102, 103, 127, 128]. These findings support the hypothesis that AURKC activity 
may be involved in dasatinib-resistance in our K562-DR cell line by driving increased cell 
proliferation or increasing resistance to apoptosis, and further study is warranted to 
investigate AURKC’s involvement in resistance.  
 
RNA-seq comparison of the differentially expressed genes in the K562-DR cell line and 
K562 cell line revealed several differentially expressed genes that conflicted with reports 
from previous studies. It is important to remember that this study is based on TKI-
resistant cell lines generated in a cell culture setting, and the resulting findings provide 
nothing more than a preliminary direction to explore. Further study of our results with 
human patient samples is necessary to validate any novel biomarkers or mechanisms of 
resistance.  
 
2.3.4 Common Features of K562-TKIr Cell Lines 
Treatment of CML is expensive, and the longer a patient fails to respond to therapy, the 






differences between imatinib, nilotinib, and dasatinib resistant cell lines, it is equally 
important to identify any common themes linking resistance to imatinib, nilotinib, and 
dasatinib in order to suggest novel resistance mechanisms or biomarkers shared by 
resistant cell lines. We have identified 24 significantly differentially expressed genes that 
were identified in K562-IR, K562-NR, and K562-DR cell lines that could serve as potential 
biomarkers of TKI-resistance, or contribute to TKI-resistance mechanisms. Table 4 lists 
these genes below.  
 
Table 4. K562-TKI-resistant cell line genes found to have significant (p>0.05) 
differential expression with respect to parental K562 cells determined by RNA-seq. 
Differential expression was analyzed using Cufflinks on the Galaxy platform. Fold change 
is expressed in terms of log2.   
 
  





ACP5 3.472 4.7 2.907 phosphatase 
AURKC -1.144 -0.689 2.45 serine/threonine kinase 
AXL 2.784 2.679 2.766 tyrosine kinase 
C3 -0.967 -1.876 -1.024 peptidase 
CD33 -2.589 -0.711 -1.725 other 
CYP2S1 2.616 2.246 2.475 enzyme 
CLEC11A 2.175 2.08 1.252 growth factor 
LRRC4B 3.301 1.385 3.057 other 







Table 4 Continued. 
KLK1 1.357 1.106 1.84 peptidase 
KLK13 1.793 2.437 1.913 peptidase 
KCNN4 1.494 1.429 2.157 ion channel 
JUNB 1 0.676 0.731 transcription factor 
NFIX -1.303 -2.261 -1.083 transcription factor 
PPP1R13L 1.941 1.559 2.138 transcription factor 
RASGRP4 -2.967 -1.608 -2.08 other 
RRAS 1.534 2.01 0.937 enzyme 
TLE2 -2.527 -1.451 -1.329 transcription factor 
TNFSF9 1.653 1.682 0.87 cytokine 
TNNI3 2.553 2.251 2.457 transporter 
TUBB4A -1.137 -2.422 -0.915 other 
VSIG10L 1.309 1.815 1.248 other 
ZNF85 2.838 2.464 2.973 trancription factor 
ZNF433 -2.288 -1.942 -3.861 transcription factor 
 
Based on our RNA-seq results we selected several candidate genes to assess their 
significance in TKI-resistance. We chose to ablate AXL as a positive control for our K562-
IR and K562-NR cell lines, as it had previously been described as a mediator of imatinib 
and nilotinib resistance, but had not been previously described in dasatinib 
resistance[42, 105]. ACP5 and CYP2S1 were chosen for further investigation, as their 
upregulation were novel findings in a CML model.  
We first had to confirm whether the increase in transcription correlated with protein 
expression. Figure 1 below confirms that protein expression of each gene is increased in 








Figure 1. Protein expression is increased in TKI-resistant cell lines. Cells were grown to 
7.5x105 cells/mL and processed for western blot analysis. AXL, ACP5, and CYP2S1 
protein expression was increased in all TKI-resistant cell lines.  
 
AXL is part of the TAM family of receptor tyrosine kinases and is activated upon binding 
to the extracellular ligand GAS6. Upon binding, AXL initiates a signaling cascade 
influencing cell migration, aggregation, and proliferation[129, 130]. AXL is known to be 
integral to the proliferation, metastasis, and contributes to drug resistance in breast, 
lung, prostate, ovarian, and many other cancers[131-134]. Because of its high 
expression and contribution to drug resistance in so many cancers, AXL is an enticing 
drug target for small-molecule inhibitors. However, AXL has been shown to contribute 
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function[42, 105]. We found AXL transcription to be upregulated in K562-IR (log2 fold 
change of 2.784), K562-NR (log2 fold change of 2.679), and K562-DR (log2 fold change of 
2.766) cell lines when compared to the parental K562 cell line. Despite having been 
implicated in imatinib and nilotinib resistance, AXL has never been implicated in 
dasatinib resistance. AXL mediates nilotinib resistance through LYN, and because 
dasatinib inhibits the kinase activity of LYN, we sought to determine if knockdown of 
AXL using siRNA in K562-DR cells inhibited proliferation relative to the K562 parental cell 
line in the same way it does in the K562-IR and K562-NR cells, or if inhibition of AXL 
kinase activity could inhibit proliferation in K562-DR cells. The results of the experiment 
confirmed previous reports that knockdown of AXL in imatinib and nilotinib resistant 
cells resensitized the cells to imatinib and nilotinib in a significant manner. The K562-IR 
cells were equally sensitive to imatinib as the parental K562 cells, and the knockdown of 
AXL in K562 cells did not have any effect on the proliferation of K562 cells in response to 
imatinib (Figure 2A). This indicates that AXL is an important mediator of acquired 
imatinib-resistance. Similarly, the knockdown of AXL in K562-NR cells restored sensitivity 
to nilotinib in the same manner as seen in the K562-IR cells (Figure 2A & 2B). However, 
the resensitization in the K562-DR cell line was modest. The proliferation of K562 cells 
and K562-DR cells was largely unaffected by AXL knockdown (Figure 2C), which may be 
indicative that the role of AXL in K562-DR cells is not as vital to TKI-resistance as it is in 
K562-IR and K562-NR cells, where it acts as a scaffold to stabilize LYN and drive 
proliferation[42, 105]. Dasatinib inhibits LYN kinase, so it is unlikely that the 






AXL does not affect dasatinib resistance, which may proceed through a different set of 
compensatory mechanisms than imatinib and nilotinib resistance. 
 
Figure 2. Knockdown of AXL Preferentially Sensitizes K562-IR Cells to imatinib, and 
K562-NR cells to nilotinib, but does not preferentially sensitize K562-DR cells to 
dasatinib. Cells were transfected with 100nM AXL siRNA for and seeded in 96-well 
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plates for 24 hours before treatment with the indicated inhibitor (n=3). A) Knockdown 
of AXL resensitizes K562-IR cells to imatinib. B) Knockdown of AXL resensitizes K562-NR 
cells to nilotinib. C) Knockdown of AXL modestly resensitizes K562-DR cells to dasatinib. 
 
 
Figure 3. Confirmation of AXL Knockdown for XTT Assay. Cells were transfected with 
100nM AXL siRNA and dosed with the indicated inhibitors 24 hours later. Seventy-two 
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hours post-transfection 1x106 cells were lysed and subjected to western blot analysis. A) 
Knockdown of AXL was successful in K562 and K562-IR cells. B) Knockdown of AXL was 
successful in K562 and K562-NR cells. C) Knockdown of AXL was successful in K562 and 
K562-DR cells. 
 
Tartrate-resistant acid phosphatase 5 (ACP5) is the only acid phosphatase not inhibited 
by L(+)tartrate. Bone resorption and osteoclast differentiation are directed by ACP5 
through modulation of focal adhesion kinase (FAK) but ACP5 is also a primary driver of 
metastasis and invasiveness in several cancers, and upregulation has been correlated 
with poor prognosis. Overexpression of ACP5 drives invasiveness and metastasis in 
hepatocellular carcinoma and human melanoma[135, 136], and it is highly upregulated 
in gastric cancer, breast cancer, and bone metastases from breast cancer patients[137-
140]. ACP5 expression has not been studied in any human leukemia, but the significant 
upregulation of ACP5 transcription in all three TKI-resistant cell lines compared to the 
parental K562 cell line (log2 fold change of 3.472, 4.700, and 2.907 in K562-IR, K562-NR, 
and K562-DR cells, respectively) along with the many reports of increased ACP5 levels 
coinciding with increased invasiveness and metastasis in other cancers led us to validate 
the effect of upregulated ACP5 in TKI-resistance in CML. Interestingly, we observed a 
pronounced sensitivity to imatinib and nilotinib (Figure 4A & 4B), but a negligible 
resensitization to dasatinib (Figure 4C). The knockdown of ACP5 in K562-DR cells and 






dasatinib, indicating that ACP5 is not likely a primary driver of dasatinib-resistance 
(Figure 4C). In both K562-IR and K562-NR cells, knockdown of ACP5 had a similar effect 
as the knockdown of ACP5 in K562 cells, suggesting that the upregulation of ACP5 may 
be correlated with acquired resistance to imatinib and nilotinib, respectively (Figure 4A 
& 4B). ACP5 is a marker of poor prognosis in other cancers, but the specific mechanism 
by which ACP5 mediates oncogenesis is unclear[135, 136, 138, 141]. Future studies may 








Figure 4. Knockdown of ACP5 Preferentially Sensitizes K562-IR Cells to imatinib, and 
K562-NR cells to nilotinib, but does not preferentially sensitize K562-DR cells to 
dasatinib. Cells were transfected with 100nM ACP5 siRNA for and seeded in 96-well 
plates for 24 hours before treatment with the indicated inhibitor (n=3). A) Knockdown 
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Figure 5. Confirmation of ACP5 Knockdown for XTT Assay. Cells were transfected with 
100nM ACP5 siRNA and dosed with the indicated inhibitors 24 hours later. Seventy-two 
hours post-transfection the cells were lysed and subjected to western blot analysis. A) 
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Knockdown of ACP5 was successful in K562 and K562-IR cells. B) Knockdown of ACP5 
was successful in K562 and K562-NR cells. C) Knockdown of ACP5 was successful in K562 
and K562-DR cells. 
 
Maintaining consistent levels of TKI in the cell is a critical factor affecting the efficacy of 
TKI treatment. CYP2S1 is a cytochrome p450 isoform that is upregulated in colorectal 
cancer and its high expression is a marker of poor prognosis in colorectal cancer. It has 
also been shown to inactivate benzothiazole antitumor compounds in breast and 
colorectal cells, and the ablation of CYP2S1 resulted in increased sensitivity to 
chemotherapy [142, 143].  In all three of our K562-TKI resistant cell lines we observed a 
marked increase in the transcription of CYP2S1 (log2 fold change of 2.616, 2.246, and 
2.475 in K562-IR, K562-NR, and K562-DR cells, respectively).  We hypothesized that 
increased CYP2S1 activity may reduce TKI activity, allowing for drug resistance to evolve, 
and siRNA-mediated knockdown of CYP2S1 would restore TKI-sensitivity in the K562-TKI 
resistant cells. CYP2S1 knockdown yielded mixed results. In the K562-IR cell line, the 
knockdown of CYP2S1 dramatically increased the sensitivity of K562-IR cells to imatinib, 
but also increased the resistance of K562 cells to imatinib, suggesting that the increase 
in CYP2S1 transcription is not a mechanism by which K562 cells acquire imatinib-
resistance (Figure 6A). The knockdown of CYP2S1 in K562-NR cells did not have an 
appreciable affect on the sensitivity of K562 or K562-NR cells to nilotinib, and we 






Knockdown of CYP2S1 did increase the sensitivity of both K562 cells and K562-DR cells 
to dasatinib, further illustrating the differences in compensatory mechanisms 
contributing to acquired resistance to dasatinib as compared to acquired imatinib and 
nilotinib resistance (Figure 6C). Given the kinase inhibition profile of dasatinib, it is not 
surprising that the knockdown of a variety of different transcripts would yield results 








Figure 6. Knockdown of CYP2S1 Preferentially Sensitizes K562-IR Cells to imatinib, and 
K562-DR cells to dasatinib, but does not preferentially sensitize K562-NR cells to 
nilotinib. Cells were transfected with 100nM CYP2S1 siRNA for and seeded in 96-well 
plates for 24 hours before treatment with the indicated inhibitor (n=3). A) Knockdown 
of CYP2S1 resensitizes K562-IR cells to imatinib. B) Knockdown of CYP2S1 modestly 
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resensitizes K562-NR cells to nilotinib. C) Knockdown of CYP2S1 does not resensitize 
K562-DR cells to dasatinib. 
 
 
Figure 7. Confirmation of CYP2S1 Knockdown for XTT Assay. Cells were transfected 
with 100nM CYP2S1 siRNA and dosed with the indicated inhibitors 24 hours later. 
Seventy-two hours post-transfection the cells were lysed and subjected to western blot 
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analysis. A) Knockdown of CYP2S1 was successful in K562 and K562-IR cells. B) 
Knockdown of CYP2S1 was successful in K562 and K562-NR cells. C) Knockdown of 
CYP2S1 was successful in K562 and K562-DR cells. 
 
2.3.5 Emergent Transcripts in the K562-TKI Resistant Cell Lines 
The goal of this study is to identify novel biomarkers of imatinib, nilotinib, and dasatinib 
resistance, and elucidate potential mechanisms underlying the development of acquired 
resistance to TKI therapy. As a patient undergoes treatment with imatinib, nilotinib, or 
dasatinib, signaling pathways will be altered in response to the inhibition of the BCR-ABL 
signaling pathway, and compensatory pathways may be activated to drive cellular 
proliferation, division, or apoptosis. As these signaling pathways are perturbed and 
resistance is acquired, the expression of genes will be disrupted to reflect the 
restructuring of cellular signaling pathways and other cellular functions to 
accommodate sustained proliferation. One potentially useful approach to identifying if a 
patient is acquiring resistance to TKI therapy is to monitor the emergence or 
disappearance of mRNA transcripts that are associated with TKI resistance. We have 
identified six transcripts displaying a fragments per kilobase of transcript per million 
mapped reads (FPKM, which is an expression of the raw number of transcripts read in a 
given sample) of greater than ± 10 in the K562-TKI resistant cell lines in relation to the 







Table 5. Emergence or Disappearance of mRNA Transcripts as Tyrosine Kinase 
Inhibitor Resistance is Acquired. Raw transcript measurements from RNA-seq analysis 
are shown in FPKM. The denoted change for K562-IR, K562-NR, and K562-DR cell lines is 
relative to the parental K562 cell line.  
Cell Line Gene FPKM Change Relative to K562 
K562-IR CLC -19.404 
  GNG8 79.085 
  MIR3940 8.49E+03 
  MIR637 1.15E+04 
  RLN3 12.707 
  SGK110 13.447 
  SNORD88A 1.07E+04 
  SNORD88B 1.08E+04 
K562-NR SNORD88C -1.09E+04 
  ZNF350 -17.451 
  GNG8 45.339 
  IGFL2 10.626 
  RLN3 43.822 
  SNORD33 2.78E+04 
  SNORD35A 7.22E+04 
K562-DR SNORD88C -1.31E+04 
  CREB3L3 15.809 
  GNG8 40.468 
  SGK110 17.982 
 
The loss of CLC in K562-IR cells is somewhat intriguing, as it is a lysophospholipase 






but very little is known about its potential role in leukemia. RLN3 (expressed in K562-IR 
and K562-NR cells) and SGK110 (expressed in K562-IR and K562-DR cells) have never 
been described in any cancer studies, and SGK110, an SH3-domain binding 
serine/threonine kinase, has never been characterized in any capacity. Further study 
into the functions of these genes in TKI-resistance may yield promising results. The loss 
of ZNF350 expression in K562-NR cells is noteworthy, as methylation of the promoter 
region and subsequent loss of ZNF350 expression has been reported in tamoxifen-
resistant breast cancer cells. Treatment with 5-aza-2ꞌdeoxycitidine significantly reduced 
promoter methylation, and the resulting increase in ZNF350 expression corresponded 
with tamoxifen re-sensitization in MCF-7 breast cancer cells[145]. Perhaps a similar 
event is the reason for ZNF350 transcriptional downregulation. The other novel 
transcript found in K562-NR cells, IGFL2, has been shown to be upregulated in Sezary 
syndrome, a rare form of CD4+ cutaneous T-cell lymphoma, although no causative 
explanation was reported[146]. CREB3L3 is a protein belonging to the cAMP-dependent 
family of transcription factors, which is activated by ER-stress in hepatocellular 
carcinoma. Activated CREB3L3 then promotes cell proliferation via c-JUN mediated 
activation of AP-1 target genes[147]. CREB3L3 is also upregulated in response to 
treatment with the putative antimetastatic agent silibinin, suggesting a possible role in 
drug-resistance in hepatocellular carcinoma[148].  
The modest increase in transcript levels of GNG8 in K562-IR, K562-NR, and K562-DR cell 






pathways, and has also been implicated in chronic lymphocytic leukemia 
pathogenesis[149]. The WNT/β-catenin pathway is activated by BCR-ABL in CML 
pathogenesis, but TKI-mediated inhibition of BCR-ABL signaling abrogates WNT/β-
catenin activity in imatinib-sensitive cells, and pharmacological inhibition of the WNT/β-
catenin pathway in combination with imatinib treatment dramatically reduced the 
amount of leukemia stem cells in a mouse model of CML[150]. Recently, sustained WNT 
signaling was demonstrated in TKI-resistant CML stem cells via expression of the tumor 
necrosis factor ligands CD70 and CD27[151]. Activation of the WNT/β-catenin signaling 
pathway in imatinib-resistant CML has been reported in many studies, but has not been 
reported in nilotinib or dasatinib resistant CML patients. It is tempting to speculate that 
emergence of the GNG8 transcript may underlie activation of the WNT/β-catenin 
signaling pathway, conferring resistance to imatinib, nilotinib, and dasatinib, but further 
study is necessary to tease apart any potential involvement of GNG8 in WNT/β-catenin-
mediated TKI-resistance.  
 
The differential expression of miR3940, miR637, snORD33, snORD35A, snORD88A, 
snORD8B, and snord88C transcript levels are tremendous in comparison to the other 
emergent transcripts. miR3940 has been shown to be downregulated in non-small cell 
lung carcinoma[152], but those data were based on a correlation between decreased 
miR3940 expression and the increasing severity of tumor growth and no oncogenic role 






the inhibition of hepatocellular carcinoma progression through the disruption of STAT3 
signaling, which rescues cells from apoptosis and promotes cell proliferation[153]. It is 
surprising that both miRNAs were found to be significantly overexpressed in the K562-IR 
cell line, when they were found to be significantly downregulated in lung and liver 
cancer tissue in the studies previously described. snORD88A, snORD88B, and snORD88C 
are small non-coding RNA’s that function to modify the biogenesis of other small 
nuclear RNA’s. Very little is currently known about the function of snORD88A, 
snORD88B, and snORD88C, but it is predicted that they can suppress gene expression in 
a miRNA-like manner[154]. Interestingly, transcription of snORD88C is lost in K562-NR 
and K562-DR cells, while it is significantly upregulated in K562-IR cells. Regardless, a 
complete understanding of the function of these transcripts is not always necessary to 
use as a benchmark for therapeutic performance, and miR3940, miR637, snORD88A and 
snORD88B could have potential as biomarkers of imatinib resistance.  
 
2.3.6 Novel Fusion Transcripts in the TKI-Resistant Cell Lines 
In addition to differential expression testing and the emergence or disappearance of 
transcripts in the K562-TKI resistant cell lines relative to the parental K562 cell line, the 
detection of novel fusion genes represents a novel biomarker avenue to detect 
emerging TKI-resistance. Fusion genes are known drivers of oncogenesis, and the 






cancers. Chronic myelogenous leukemia is induced by the development of the BCR-ABL 
fusion gene, and oncogenesis can be spurred by the fusion of a gene to a strong 
promoter region, allowing for increased transcription of an oncogene, or elimination of 
an inhibitory residue, which induces a constitutively active oncogene. In every replicate 
from each of our conditions we identified transcription of the BCR-ABL fusion gene, 
which served as an internal positive control for gene fusion detection. Additionally, we 
identified several novel fusion genes in our TKI-resistant cells that have not been 
previously reported.  
 
We used the DeFuse software to identify fusion genes present in our TKI-resistant cell 
lines in an effort to identify potential drivers of resistance or biomarkers that could be 
potentially used to detect impending TKI resistance at an early stage. Novel fusion genes 
detected in our RNA-seq results are listed in Table 6 below.  
 
Table 6. Novel Fusion Genes Present in K562-TKI Resistant Cell Lines. Novel fusion 
genes identified from RNA-seq analysis in K562-IR, K562-NR, and K562-DR cells are 
shown. Fusion genes were identified using DeFuse software on the Galaxy platform 












K562-IR ANAPC1 RMND5A 11 8 
 
RPL11 TCEB3 23 23 
 
CTSC RAB38 8 8 
K562-NR RPL11 TCEB3 23 23 
K562-DR CTSC RAB38 8 8 
 
RPL11 TCEB3 23 23 
 
We were able to identify three fusion genes not previously described in a CML model, 
which were not present in the parental K562 cell line. ANAPC1-RMND5A had previously 
been reported in BT474 and SKBR3 breast cancer cells, and had been identified as a 
mutation driving oncogenesis[155], and could potentially play a role in imatinib 
resistance in our K562-IR model. The RPL11-TCEB3 fusion had not yet been described in 
CML cells, but its identification was not surprising, as they are found on the same locus. 
The detection of the RPL11-TCEB3 fusion transcript was not a read-through error, 
despite their proximity on the same locus. Interestingly, both RPL11 and TCEB3 have 
been described as tumor-suppressors in other cancers[156, 157]. Although it is outside 
our current scope, it would be interesting to determine whether the fusion of these 
genes results in a functionally inactive protein that undermines their ability to suppress 
tumorigenesis. The last fusion gene detected was CTSC-RAB38, which is found in 






Functional studies are required to determine any contribution these novel fusion 
transcripts may have to TKI-resistance in CML, but their identification may allow them to 
be implemented as biomarkers of treatment failure. It may be possible to identify 
emergence of these novel fusion proteins using transcriptomics or mass spectrometry to 
monitor a patient’s response to treatment, or predict if a patient will elicit a favorable 
response to a particular TKI prior to treatment. 
 
2.3 Conclusions 
We report a transcriptomics-based characterization of a cell-culture model of acquired 
resistance to imatinib, nilotinib, and dasatinib, respectively, in chronic myelogenous 
leukemia. Although there are differences in transcription profiles between the TKI-
resistant cells, we report twenty-four genes all three cell lines significantly differentially 
expressed with respect to the parental K562 cell line. Additionally, we report the 
emergence and disappearance of transcripts in our TKI-resistant cell lines with respect 
to the parental cell line, with GNG8 a common emergent transcript. Finally, we report 
novel fusion transcripts unique to each imatinib, nilotinib, and dasatinib. This 
bioinformatics approach must be followed up with data from patient samples, but the 
results of our cell-culture model may serve as a guide to direct further research into the 
acquisition of resistance to imatinib, nilotinib, and dasatinib, and lead to the 







CHAPTER 3. IDENTIFICATION OF PROTEOMIC DIFFERENCES BETWEEN WILD-TYPE CML 
CELLS AND CML CELLS RESISTANT TO TYROSINE KINASE INHIBITORS  
3.1 Introduction 
Proteomics is the study of the proteins present in a particular sample, which extends the 
understanding of the physiological functions of the genes that transcribe them. Proteins 
are modified through posttranslational modifications that alter the structure and 
activity of the proteins and can affect the rates of degradation of proteins in a complex 
spatiotemporal manner. The constant changes in rates of degradation and synthesis of 
proteins makes proteomics a dynamic field much more complex than genomics or 
transcriptomics. Tyrosine kinase inhibitors enact cellular change by acting at the 
proteinlevel; therefore it is prudent to study the changes occurring at the cellular level 
at which most signaling occurs, the protein level. In this chapter I examine the 
proteomic differences between the parental K562 cell line and the K562-IR, K562-NR, 
and K562-DR cell lines, respectively, using Sequential Window Acquisition of all 






3.2 Materials and Methods 
 
Generation of TKI-resistant Cell Lines. Described in Chapter 2. 
 
Sample Preparation for Proteomic Analysis.  K562, K562-IR, K562-NR, and K562-DR cell 
lines were thawed and grown in IMDM supplemented with 10% FBS and 0.1% 
penicillin/streptomycin. The cells were grown to a density of ~7.5x105 cells/mL, and 
1x107 cells of each cell line were centrifuged and washed three times with ice-cold PBS. 
The cells were then resuspended in lysis buffer (50mM ammonium bicarbonate pH 7.0, 
4mM EDTA, phosphatase inhibitors (Roche)) and immediately incubated at 95°C for five 
minutes. The cells were then sonicated for 30 minutes in a water-bath and the insoluble 
fraction was separated from the cell lysate by centrifugation at 1.5x103 RPM for 20 
minutes at 4°C. Each sample was reduced (20mM DTT for 1 hour at 60° C), and alkylated 
(40mM IAA for 30 minutes at room temperature, protected from light). Reactions were 
quenched by adding DTT to a final concentration of 10mM. The samples were then 
trypsin digested overnight at 37° C at a ratio of 1:50 (w/w). Samples were then cleaned 
up using MCX stage-tips[143, 159] and resuspended in Triple TOF sample buffer (90% 
water/ 10% acetonitrile/ 0.1% formic acid) to a final concentration of 0.15 mg/mL and 
transferred to mass spectrometry sample vials (Eksigent). 
SWATH-MS analysis. Eight hundred nanograms of each sample were loaded onto a 3 






serial mode with a Eksigent 400 cHIPLC system. The run gradient was over 90 min with a 
gradient from 5% to 35% buffer B (buffer A: LC-grade water + 0.1% formic acid; buffer B: 
LC-grade acetonitrile + 0.1% formic acid) at a flowrate of 300 nl/min. The Eksigent 400 
cHIPLC system was coupled to a TripleTOF 5600 (SCIEX) mass spectrometer. The 
acquisition parameters were as follows: one 50 msec MS scan (at >30K resolution), 
followed by 34 SWATH windows of 25 da each at 50 msec accumulation time for m/z 
400-1250. The total cycle time was ~1.8 sec and each analysis was performed in 
duplicate.  
 
Analysis of SWATH-MS Data Using DIA-Umpire. DIA files were first converted to 
centroided mzXMLs with the Sciex MS Data Converter. DIA Umpire signal extraction 
module was used to detect peptide fragment features based on m/z and retention time 
information and construct 'pseudospectra' for potential peptides[160]. The Q1 and Q3 
level pseudospectrum MGF file outputs from DIA Umpire SE were converted to indexed 
mzXML and searched against a human swissprot reference database using the Comet 
and xtandem! native and xtandem! kscore algorithms via the trans proteomic pipeline 
(v4.8.0). Search outputs were converted to pep.xml files and peptide probability 
modeling was performed using the xinteract peptide prophet algorithm (using high mass 
accuracy binning, retention time information, and non-parametric decoy modeling). 
Search results corresponding to one raw file generated by the three separate algorithms 






loaded into Skyline software to construct an peptide transition assay library of all 
peptide spectral matches with probability scores > 0.95. The five peptide fragments with 
highest intensities (excluding fragments within 3 residues of either the C- or N-terminus) 
were used to represent each peptide. The assay list was filtered to include only 
proteotypic (e.g., unique to a single protein sequence, non-degenerate) peptide 
sequences and decoys with shuffled sequence were appended to the list. This final 
transition assay list was extracted against each of the individual DIA files for targeted re-
analysis and peptide quantification in Skyline. False discovery rates were estimated with 
the mprophet algorithm feature, and peptides with FDR < 0.01 were exported for 
statistical processing in MSSTATS (v3.2.2). Data were normalized to median signal 
intensities and protein inference was estimated using the Tukey's Median Polish based 
protein abundance modeling algorithm. Pairwise comparisons were calculated between 
experimental groups of interest, and Bonferonni adjusted p-values were used to control 
for multiple testing effects. 
 
3.3 Proteomics as a Cancer Biomarkers 
One of the primary limitations of transcriptomics-based biomarker identification is that 
the output does not reveal any information about the activity of the resulting protein, or 
even if the protein is ultimately translated. miRNA and other non-coding RNA play a 
substantial role in mRNA translation and protein synthesis[161-163], and dynamic 






on transcriptomic data. There is a need to identify protein activity levels in disease 
pathology, as mRNA levels do not strongly correlate with protein levels, and it is 
impossible to determine the activity of a protein from its mRNA[164]. Recent advances 
in mass spectrometry-based proteomics have dramatically improved the ability to 
detect proteins and their post-translational modifications in complex protein mixtures, 
such as cell lysate. Mass-spectrometry based proteomics has traditionally been 
dominated by two complimentary modes of detection. Bottom-up discovery 
proteomics, or “shotgun proteomics”, utilizes high-performance liquid chromatography 
in combination with a tandem mass-spectrometer to identify peptides from complex 
mixtures based on the spectral profile of the MS2 fragmentation pattern. Shotgun 
proteomics is useful for determining the proteins in a given sample, but is limited by the 
large m/z range over which the instrument is required to detect fragment ions. The 
resulting data is heavily biased toward the most abundant MS1 precursor peptides, and 
excludes low-abundance proteins from being identified. Targeted proteomics, or 
selected-reaction monitoring (SRM), is the monitoring of the products of a precursor ion 
at a specific m/z range in an effort to quantify a specific protein in a sample. Targeted 
proteomics requires the researcher to know the identity of their protein of interest in 
order to monitor its detection, whereas shotgun proteomics is useful for discovering 
proteins present in a sample. A recent advance in mass-spectrometry has effectively 
combined the advantages of SRM and shotgun proteomics into one method, allowing 






3.3.1 Use of SWATH-Mass Spectrometry in Biomarker Research 
Sequential Window Acquisition of All Theoretical Spectra (SWATH-MS) is a data-
independent acquisition (DIA) mass-spectrometry method capable of detecting all MS2 
fragment ions generated from all MS1 precursor ions eluting from an HPLC column in a 
given sample, thus generating a permanent digital library of all detectable fragment ion 
spectra within the instrument’s dynamic range. In SWATH-MS experiments, the mass 
spectrometer steps through 2-4 second cycles in which all precursor ions eluting from 
the HPLC column at a given time are fragmented, and the mass spectrometer rapidly 
detects the resulting fragment ions. Unlike in Data Dependent Acquisition (DDA) 
methods, where only a set of the most abundant MS1 precursor ions are fragmented for 
MS2 analysis, DIA offers an opportunity to both identify and quantify an enormous 
number of proteins in a complex protein mixture, such as cell lysate, combining the level 
of peptide coverage afforded by shotgun proteomics with the sensitivity and 
quantification of SRM. SWATH-MS is a very versatile tool for cell biology research, 
having been used to identify 14-3-3 protein-binding partners, biomarkers of prostate 
cancer aggressiveness, and even cannabinoid metabolites found in urine[165-167]. 
Transcription of a gene does not significantly correlate with its translation or protein 
activity upon translation[164, 168, 169], and the bias of shotgun proteomics toward 
high abundance proteins makes the use of SWATH-MS an ideal solution to identify novel 
protein biomarkers of TKI-resistance in chronic myelogenous leukemia that may be 
present at lower abundances and undetectable using a conventional DDA approach. We 






lines for potential biomarkers of TKI resistance, and compare the protein composition of 
each cell line with their transcriptome. 
 
3.4 Proteomic Changes in K562 Cells as Compared to K562-TKI Resistant Cells 
We sought to compare the transcriptomic changes in K562 cells with evolved resistance 
to imatinib, nilotinib, and dasatinib with the proteomic changes in the same cell line to 
determine if the transcription levels correspond with the observed protein levels. The 
complex relationship between transcription and translation has been well documented, 
as miRNA and other factors effect the translation of mRNA into proteins and dynamic 
changes in the rates of protein degradation affecting protein levels after translation. 
SWATH-MS was used to quantify the proteins present in K562 cells and K562-TKIR cells. 
DIA-Umpire was then used to extract pseudo-MS spectra. DIA-Umpire is an open-source 
software program that allows for untargeted peptide identification from DIA mass 
spectrometry data without the use of a spectral library created from DDA data. DIA-
Umpire works by incorporating several computer algorithms to detect all possible 
precursor fragment ions signals in MS1 and MS2, including unfragmented ions in MS2 
data. The algorithm then computes the Pearson correlation coefficient of the retention 
time and peak apex of eluting fragment ions to determine the likelihood that a 
particular fragment ion corresponds to a precursor ion. The precursor-fragment groups 
are then grouped together as pseudo-MS/MS spectra that are searchable in 
conventional protein databases[160]. The Q1 and Q3 level pseudo-spectrum MGF file 






human swissprot reference database using the Comet and X!Tandem native and 
X!Tandem kscore algorithms via the trans proteomic pipeline (v4.8.0)[170]. Search 
outputs were converted to pep.xml files and peptide probability modeling was 
performed using the xinteract peptide prophet algorithm (using high mass accuracy 
binning, retention time information, and non-parametric decoy modeling). Search 
results corresponding to one raw file generated by the three separate algorithms were 
combined using the interprophetparser. The final, combined search result was loaded 
into Skyline software to construct a peptide transition assay library of all peptide 
spectral matches with probability scores > 0.95. The five peptide fragments with highest 
intensities (excluding fragments within 3 residues of either the C- or N-terminus) were 
used to represent each peptide. The assay list was filtered to include only proteotypic 
(e.g., unique to a single protein sequence, non-degenerate) peptide sequences and 
decoys with shuffled sequence were appended to the list. This final transition assay list 
was extracted against each of the individual DIA files for targeted re-analysis and 
peptide quantification in Skyline[171, 172]. False discovery rates were estimated with 
the mprophet algorithm feature, and peptides with FDR < 0.01 were exported for 
statistical processing in MSSTATS (v3.2.2)[171, 172]. Data were normalized to median 
signal intensities and protein inference was estimated using the Tukey's Median Polish 
based protein abundance modeling algorithm. Pairwise comparisons were calculated 
between experimental groups of interest, and Bonferonni adjusted p-values were used 
to control for multiple testing effects. The construction of the spectral library using DIA-






Parker. Across all of the TKI-resistant samples, we found 69 proteins that were 
significantly downregulated compared to the parental K562 cells (p<0.05), and 32 
proteins that were significantly upregulated compared to the parental K562 cells 
(p<0.05). We chose to include proteins with a log2 fold change of ±2 in our report, and 
significantly differentially expressed proteins in K562-IR cells as compared to K562 cells 
are listed in Table 7 below.  
 
Table 7. K562-IR proteins found to have significant (p<0.05) differential expression 
with respect to parental K562 cells determined by SWATH-MS. Differential expression 
was analyzed using Skyline, and statistics were compiled using MSStats.  
 
Protein log2 Fold Change p-value 
PHB2 2.463 4.76E-02 
PURA 2.378 4.34E-05 
CAST -2.441 3.66E-02 
AHNAK2 -2.524 3.39E-03 
KRT6B -2.716 3.32E-04 
NUCKS1 -2.787 2.15E-03 
CA1 -3.017 1.14E-04 
KRT10 -3.229 2.71E-05 
DSC1 -3.422 1.74E-02 
KRT1 -3.515 7.16E-07 
KRT14 -3.734 5.10E-03 
KRT9 -3.976 7.52E-05 
CALML5  -4.691 1.25E-03 
DSG1 -5.044 5.64E-03 






Table 7 Continued. 
KRT5 -5.167 5.70E-03 
DSP -6.283 2.35E-03 
KRT16 -6.917 2.48E-02 
JUP -7.68 3.16E-02 
 
One striking feature of the K562-IR cell line is the increased protein levels of only two 
proteins, and seventeen downregulated proteins. There are also six proteins that have a 
log2 fold change of -5.0 or more, which is more differentially expressed than any gene 
found in our RNA-seq experiments. Of note are the most positively and negatively 
differentially expressed proteins. PHB2 is a mediator of transcriptional regulation, and 
mutational studies have demonstrated its roles in driving ERK1/2 signaling, inhibition of 
apoptosis, release from the G1/S checkpoint in mitosis, and protein stabilization[173-
175].  
 
On the other hand, the significant loss of JUP, DSG1, and DSP, along with eight proteins 
members of the keratin-family is interesting; all eleven proteins have been shown to 
mediate cell to cell adhesion by forming desmosomes[176-178], the loss of which is a 
common feature of cancer[179]. Part of the desmosome complex is the metastasis-
suppressing protein VE-cadherin, which forms a complex with JUP and several keratins 
to mediate cell-cell adhesion and prevent cell motility, however, loss of VE-cadherin has 






loss of the remaining components of the desmosome complex, which may be indicative 
of their role in acquired imatinib resistance. A hallmark of the metastatic process in 
recurrent cancer is the epithelial-to-mesenchymal transition (EMT), which is 
characterized by a loss of E-cadherin, and upregulation of N-cadherin (EN-switch)[181]. 
N-cadherin forms a cytoplasmic complex with β-catenin, increasing Wnt-mediated β-
catenin nuclear translocation and transcriptional activity, and plays a role in TKI 
resistance in leukemia stem cells (LSC) in CML cells co-cultured with bone marrow 
stromal cells[182]. The loss of the desmosome complex could potentially be a by-
product of the K562-IR cell line acquiring a phenotype similar to LSCs in the context of 
the bone marrow microenvironment, which helps to confer imatinib resistance.  
 
The overexpression of AXL could potentially mediate the loss of the desmosome 
complex in K562-IR cells. EMT is the process by which cells metastasize, and the loss of 
the desmosome is necessary for EMT to occur. AXL has been shown to be integral to 
EMT progression and the disruption of cell-cell adhesion[183]. The overexpression of 
AXL is also highly correlated with increased Wnt and TGFβR signaling, which are also 
upregulated during EMT, and associated with the loss of the desmosome complex and 
the EN-switch[184]. The association between AXL upregulation and the loss of the 
desmosome complex would mark a yet-uncharacterized link between the receptor 
tyrosine kinase and the desmosome complex. Leukemia stem cells are intrinsically 






in the disruption of the cell-cell adhesion anchoring LSCs in the bone marrow, allowing 
TKI-resistant CML cells to enter the bloodstream. Future studies should profile the 
expression of EMT-related genes such as vimentin and snail in response to AXL 
upregulation to determine in AXL upregulation corresponds with the induction of EMT-
related gene expression. Additionally, it would be interesting to determine the 
molecular time-line of AXL upregulation and the loss of the desmosome complex, which 
could be easily determined using standard western blotting. The association of AXL 
upregulation and the induction of Wnt/TGFβ signaling has not been described in CML 
models, and it would be very interesting to explore the possibility that AXL upregulation 
serves as a conduit to drive cell proliferation by activating the Wnt/TGFβ pathway, and 
the loss of the desmosome is a consequence. Leukemia stem cells are intrinsically 
resistant to imatinib, so it raises the possibility that resistance to imatinib in vivo 
progresses through upregulation of AXL and the corresponding loss of the desmosome 
complex and the release of differentiated TKI-resistant CML cells from the bone marrow. 
AXL activates the MAPK pathway, which enhances WNT signaling[185]. It would be 
interesting to dissect the interaction between AXL and WNT, and if it proceeds through 












Figure 8. Proposed Model of K562-IR Resistance. AXL activates the MAP Kinase 
pathway, activating WNT/TGFβR, which leads to the downregulation of the proteins 
composing the desmosome complex, allowing for cell motility to increase. 
Table 8. K562-NR proteins found to have significant (p<0.05) differential expression 
with respect to parental K562 cells determined by SWATH-MS. Differential expression 






SLC25A3 4.308 1.93E-04 
KRT14 3.798 4.80E-03 
RPN1 3.603 3.40E-02 
PHB2 3.546 1.53E-02 
TUBA4A 3.478 1.31E-03 
LRRC59 3.146 1.37E-04 
VDAC2 3.084 1.93E-03 
COMT 2.938 2.55E-02 
VDAC1 2.647 3.27E-05 
RHOA 2.549 4.35E-03 
HBE1 2.218 1.66E-06 
VAPA 2.202 1.08E-04 
RAB33B 2.062 3.09E-04 
RAB35 2.053 4.83E-05 
PHGDH 2.006 5.59E-04 
PEX19 -2.041 1.50E-03 
PTMS -2.045 2.06E-05 
PAGE5 -2.089 2.04E-05 
UQCRH -2.125 2.77E-05 






Table 8 Continued. 
BTF3 -2.148 5.86E-05 
NOLC1 -2.149 5.43E-04 
TMSB10 -2.159 2.36E-04 
NACA2 -2.237 1.70E-06 
RPS21 -2.238 1.13E-03 
DNAAF2 -2.251 1.00E-01 
AHNAK2 -2.284 4.13E-03 
POLR2I -2.322 5.79E-02 
SH3BGRL3 -2.338 1.05E-02 
TIMM8A -2.34 5.16E-03 
ATOX1 -2.42 4.63E-04 
ZC3H18 -2.483 2.36E-02 
GRN -2.502 5.39E-03 
TPM4 -2.533 1.51E-04 
ZPR1 -2.576 4.28E-02 
C14orf142 -2.591 3.82E-05 
SH3BGRL -2.645 4.31E-05 
AHNAK -2.747 3.25E-01 
MYL6 -2.833 3.17E-04 
COX6B1 -2.875 4.47E-04 
CCDC86 -2.876 5.17E-02 
TRIP6 -3.16 1.80E-01 
KIAA0101 -3.368 2.63E-04 
RBM3 -3.475 2.80E-02 
ZNF428 -3.563 1.09E-03 
NUCKS1 -3.704 7.28E-04 
CAST -3.727 9.19E-03 
BTF3L4 -4.169 1.78E-04 
 
The K562-NR cells followed suit with the results from our RNA-seq analysis and showed 






parental K562 cell line. However, the results also demonstrated a majority of proteins 
downregulated, as 33 of 48 significantly differentially expressed proteins bearing a log2 
fold change of ± 2 were downregulated. One of the most significantly upregulated genes 
was PHB2, a trait shared with the K562-IR cells. However, in the K562-NR cell line there 
was not a common trend of desmosome-related proteins in the downregulated group, 
with the only member of that group being KRT14, which was highly upregulated. A 
common feature of several upregulated proteins is their involvement in mitochondrial 
membrane transport, as VDAC1 and VDAC2 are upregulated in many cancers and their 
inhibition promotes apoptosis[186], and SLC25A3, a protein integral to phosphate 
transport from the cytosol to the mitochondrial matrix, has been reported to be 
significantly overexpressed in blast phase CML as compared to chronic phase CML[187]. 
Similarly, NUCKS1 upregulation is a biomarker of recurrence-free survival in cervical 
squamous carcinoma, and its downregulation is a predictor of vincristine-resistance in 
childhood acute lymphoblastic leukemia[188, 189].  
 
CAST, also known as calpain-10, is significantly downregulated in K562-NR cells as 
compared to K562 cells. CAST has been shown to be a negative regulator of apoptosis in 
pancreatic cells, and may serve a similar purpose in K562-NR cells[190]. Although there 
has been no established role of these proteins in CML, it is worth noting there has been 
some role established on other cancer models that may translate to nilotinib resistance 






Table 9. K562-DR proteins found to have significant (p<0.05) differential expression 
with respect to parental K562 cells determined by SWATH-MS. Differential expression 
was analyzed using Skyline, and statistics were compiled using MSStats. 
 
Protein log2 Fold Change p-value 
SLC25A3 3.26 2.43E-04 
COMT 3.242 3.35E-02 
ASNS 3.184 3.27E-03 
RPN1 2.887 6.42E-02 
PHB2 2.846 3.10E-02 
RAB10 2.727 9.17E-05 
SLC25A5 2.721 1.13E-03 
LRRC59 2.486 3.45E-04 
NOP16 2.287 5.08E-02 
VDAC1 2.222 6.55E-05 
TK1 2.169 1.08E-02 
CBS 2.155 3.82E-02 
VDAC2 2.154 7.19E-03 
VAPA 2.093 1.32E-04 
GCN1L1 2.06 3.03E-01 
KRT2 -2.018 3.58E-02 
C14orf142 -2.147 8.04E-05 
SH3BGRL3 -2.209 1.27E-02 
CCDC86 -2.22 1.02E-01 
PAGE5 -2.242 1.54E-05 
ZC3H18 -2.243 3.25E-02 
SH3BGRL -2.254 8.12E-05 
PTMS -2.27 1.36E-05 
TIMM8A -2.385 4.82E-03 
TRIP6 -2.391 2.04E-01 
MYL6 -2.417 5.88E-04 






Table 9 Continued. 
ZPR1 -2.639 3.99E-02 
AHNAK -2.772 3.22E-01 
CALML5 -2.899 3.27E-03 
DSG1 -3.295 1.86E-02 
NUCKS1 -3.384 1.03E-03 
CAST -3.46 1.19E-02 
BTF3L4 -3.932 2.24E-04 
 
The K562-DR cells profile of significantly differentially expressed proteins shared many 
common features with the K562-NR cells, namely, the significant downregulation of 
BTF3L4, CAST, NUCKS1, AHNAK, ZPR1, TIMM8A, SH3BGRL, ZC3H18 and MYL6, along with 
the upregulation of SLC25A3, VDAC1 and VDAC2, LRRC59, and VAPA. The upregulated 
proteins in both conditions are involved in metabolic reprogramming, and might be 
indicative of the evolution of a more general cancer-survival reprogramming. Of note is 
the high level of TK1 in K562-DR cells, a thymidine kinase, and biomarker of poor 
prognosis in chronic lymphocytic leukemia, breast, gastric, rectal, colorectal, lung, brain 
cancer, and hepatoma[191, 192].  
 
K562-DR cells also shared common downregulated proteins with K562-IR cells, such as 
DSG1, and CALML5, the ubiquitination of which has been linked to breast cancer 
carcinogenesis in premenopausal women[193]. Compared to the transcriptomic data, 






analysis of TKI-resistant K562 cells yielded only eighteen commonly significantly 
differentially expressed proteins across all three conditions.  
 
Table 10. Common proteins in TKI-resistant K562 cells found to have significant 
(p<0.05) differential expression with respect to parental K562 cells determined by 
SWATH-MS. Differential expression was analyzed using Skyline, and statistics were 
compiled using MSStats.  
 
Protein  IR log2 Fold Change NR log2 Fold Change DR log2 Fold Change 
ABCE1 1.062 1.649 1.405 
ASNS 1.954 1.91 3.184 
CA1 -3.017 -1.528 -1.632 
CAST -2.441 -3.727 -3.46 
DDX6 1.149 1.331 1.005 
DDX21 1.19 1.227 1.985 
EIF4B 1.116 -1.191 -1.295 
FKBP3 -1.322 -1.865 -1.74 
FRA10AC1 -1.439 -1.097 -1.1 
IGF2BP1 1.097 1.153 1.159 
MYL6 -1.084 -2.833 -2.417 
NFYA -1.222 -1.618 -1.589 
NUCKS1 -2.787 -3.704 -3.384 
PHB2 2.463 3.546 2.846 
SLC25A3 1.526 4.308 3.26 
SLC3A2 1.229 1.303 1.118 
TPM4 -1.231 -2.533 -1.77 







The commonly expressed proteins are involved in cell proliferation, apoptotic resistance, 
or are biomarkers of chemoresistance, but it would be premature to speculate about 
any potential role any play in TKI resistance. It may be worthwhile to probe PHB2’s role 
in ERK1/2 signaling in TKI-resistant cells. Interestingly, we observed the upregulation of 
ABCE1, an ATP-binding cassette sub-family member that is known to inhibit 
endoribonuclease activity and influences mRNA turnover. ABCE1 upregulation is found 
in several other cancers, and siRNA-mediated depletion of ABCE1 induces inhibits 
cellular proliferation, sensitizes cancer cells to chemotherapy, and induces apoptosis in 
breast, lung, and esophageal cancers[194-196]. ASNS is also upregulated in all three TKI-
resistant cell lines. ASNS catalyzes the conversion of arginine to asparagine, and is 
known to mediate cisplatin-resistance in nasopharyngeal carcinoma, doxorubicin 
resistance in uterine cancer, and is highly upregulated in melanoma and lymphoma[197-
200]. Further study of ASNS in TKI-resistance may be warranted. Also noteworthy is the 
upregulation of DDX6 and DDX21, which are ATP-dependent RNA helicases that are 
integral components of the mRNA degradation machinery. Ablation of DDX6 in 
colorectal cancer cells inhibits cell proliferation and promotes apoptosis[201, 202]. 
DDX21 is another ATP-dependent RNA helicase that was recently uncovered to be a 
crucial regulator of ribosome biogenesis, and interacts with a wide variety of RNA, 
including non-coding RNAs involved in the formation of ribonucleoprotein complexes, 
including ribosomal RNA, small nucleolar RNAs (snoRNAs) and 7SK RNA[203].  DDX21 is 
also highly upregulated in lymphomas, breast, and colon cancer, and is known to drive 






fashions[204-206]. The upregulation of DDX6 and DDX21 may play key roles in the 
imatinib, nilotinib, and dasatinib resistance in our K562-TKI resistant cell lines by 
inhibiting the synthesis of proteins involved in TKI-mediated apoptosis, and partially 
explain the dramatic differences observed between the transcriptome and proteome in 
our K562-TKI resistant cell lines. 
 
A comparison of the significantly differentially expressed genes between the 
transcriptome and proteome of TKI-resistant K562 cells with respect to the parental 
K562 cells requires less stringent differential expression requirements, as no proteins 
with a log2 fold change of ±2 were detected in both our SWATH analysis and RNA-seq 
analysis. We only detected one protein that displayed a significant fold change at the 
mRNA level and protein level across all TKI-resistant samples as compared to the 
parental K562 cell line, TPM4. 
 
Table 11. Common genes and proteins in K562-TKI resistant cells found to have 
significant (p<0.05) differential expression with respect to parental K562 cells 
determined by RNA-seq and SWATH-MS. Differential expression of proteins was 
analyzed using Skyline, and statistics were compiled using MSStats. Differential 
expression of mRNA trancripts was analyzed using Cufflinks on the Galaxy platform. Fold 







TPM4 Transcript log2 Fold 
Change 
TPM2 Protein log2 Fold 
Change 
IR 0.808 -1.231 
NR 0.467 -2.533 
DR -0.698 -1.77 
 
In both the K562-IR and K562-NR cells the transcription of TPM4 was upregulated, but 
the protein levels were downregulated, and in the K562-DR cells there was significantly 
more change in protein levels than mRNA levels, which simply demonstrates the 
transient nature of protein stability. It is possible that the protein was never translated 
from the mRNA, or the rates of protein degradation far surpassed the rates of protein 
synthesis in the K562-IR and K562-NR samples. Without further experimentation, it will 
be impossible to accurately explain the nature of this seemingly contradictory 
observation. However, it is not particularly surprising that the levels of mRNA and 
protein do not support each other, and illustrates the need to develop biomarkers of 
disease progression and response to chemotherapy at the protein level, the level at 
which most therapies exert their targeted action.  
 
Transcriptomic data and proteomic data does not necessarily correlate, as there are 
many levels of post-transcriptional and post-translational modifications that contribute 
to protein levels at any given time. Previous studies have demonstrated a significant lack 
of correlation between the transcriptome and the proteome: Ghazalpour et al found a 
correlation coefficient of only 0.27 for transcript/protein expression similarity[169], Foss 






al reported a mRNA-protein correlation coefficient of 0.22[207]. All of these studies 
support the concept that much of the level of protein expression is post-transcriptional 
and post-translational regulation. Given the significant genetic and metabolic 
reprogramming necessary to evolve resistance to imatinib, nilotinib, or dasatinib, it is 
unsurprising that our data reflects a low correlation between the transcriptome and 
proteome.  
 
One explanation for the low correlation between our RNA-seq and SWATH-MS data 
could also be the significant difference in sensitivity between the measurement 
techniques. RNA-seq is extremely sensitive, and generally detects all transcripts 
regardless of their abundance. When using SWATH-MS to analyze the proteome of a 
sample set, it is imperative to develop a spectral reference library with maximum 
coverage of the proteome, which is typically acheived by using reverse-phase 
chromatography to fractionate the samples into many fractions of the same sample, 
which are then sequentially analyzed by the mass spectrometer. Without fractionation, 
many peptides are eluted at the same time, and the results are heavily biased towards 
only the most abundant peptides, as the instrument selects the most abundant peptides 
in a given MS1 window to fractionate for MS2 detection. Fractionation allows for the 
total sample to be spread out over many analytical runs, allowing detection of less 






fractionation up-front of the mass spectrometric analysis, which severely limited the 
depth of coverage we were able to attain in our proteomic experiments. 
 
3.5 Identification of Unreported Peptides in SWATH Data 
Proteogenomics is an emerging field combining transcriptomics and proteomics to 
expand the identification of spectra collected in a proteomics experiment to the 
genome. To do this, peptides obtained from RNA-seq experiments that are not 
contained in the reference database are appended to freely available protein reference 
databases to create a custom database unique to the sample set that is being analyzed. 
This approach is particularly useful for the study of cancer pathologies, as genetic 
mutations such as the emergence of fusion genes, can yield novel peptides that are not 
contained in common protein reference databases. We used a proteogenomic approach 
to translate unreported sequences identified in our RNA-seq experiments into peptides 
we might detect in our SWATH experiments. We first used GalaxyP to convert the 
format of our raw RNA-seq data from FASTQ to FASTA, and then concatenated the 
mapped reads from our Tophat2 runs to the human GRCh37 assembly reference FASTA 
file, and filtered all of the repeated genomic sequences[92]. Next, we used a 3-frame 
translation to convert the concatenated BED files from the previous step, into a peptide 
FASTA output file containing the GRCh37 reference peptides, and the peptides unique 







file with the RNA-seq-appended reference file to filter out all shared peptides using 
BLAST-P[208]. The results are shown in Table 12 below. 
 
Table 12. Unreported peptides identified in K562-TKI resistant cells using GalaxyP. 
RNA-seq reads were appended to the GRCh37 human reference database and 
converted to a peptide FASTA file, and novel peptides were filtered from the original 
reference database to yield peptides present in our RNA-seq samples hat were not 
reported in the GRCh37 human reference database.  










Six of the eight peptides identified in our RNA-seq data did not map to a specific gene, 
and may be false positives, or map to miRNAs or genes that have yet to be characterized. 
However, we were able to match two peptides from the RNA-seq data with their 
corresponding genes. The first peptide, ARFPQQKK, mapped to the gene TRAF2, which 
regulates the activity of JNK and NFκB and plays a central role in cell proliferation and 






Unfortunately, ARFPQQKK could not be identified in the SWATH-MS data. Conversely, 
LTVAPPLAEPGAGK, a peptide corresponding to the ODO2 gene was identified in both 
the RNA-seq data and the SWATH-MS data. However, the predicted lysine residue 
(LTVAPPLAEPGAGK) identified in the transcript detected in the RNA-seq data actually 
corresponds to a proline residue (PTVAPPLAEPGAGK)in the peptide detected in the 
SWATH-MS data, which is the correct peptide according to published FASTA databases. 
RNA-seq is a highly sensitive technique, and it is likely that a very small fraction of 
transcripts contained this mutation, but were filtered as novel peptides despite very low 
transcript levels. Despite the L-P mutation, the PTVAPPLAEPGAGK peptide was still only 
identified in our database searches using the custom FASTA file derived from our RNA-
seq data. The identification of point mutations is an important goal of proteogenomics, 
as transcriptomic data does not inform about translational errors that could potentially 
be drivers of oncogenesis. By appending a data from our RNA-seq analysis with an 
existing protein database we were able to identify a mutation that would have been 
overlooked without the implementation of a proteogenomic approach. Future 
experiments will optimize our SWATH-MS methods to increase the proteomic coverage 
of our samples, and we expect that optimization of our methods will allow for 










In this chapter we report the results of a proteomic analysis of the K562-IR, K562-NR, 
and K562-DR cell lines with respect to the parental K562 cell line. Across all three TKI-
resistant cell lines we identified the upregulation of PHB2, a protein involved in cell 
proliferation, inhibition of apoptosis, and ERK1/2 signaling. In the K562-IR cells we 
observed a significant downregulation of eleven proteins involved in the formation of 
the desmosome complex. The K562-NR cell line and K562-DR cell line shared many 
common proteins differentially expressed at similar levels, namely, the significant 
downregulation of BTF3L4, CAST, NUCKS1, AHNAK, ZPR1, TIMM8A, SH3BGRL, ZC3H18 
and MYL6, along with the upregulation of SLC25A3, VDAC1 and VDAC2, LRRC59, and 
VAPA. Finally, we used a proteogenomic approach to add novel peptides identified in 
our RNA-seq experiment to generate a custom FASTA file for which to search our 
SWATH-MS data against. We were able to identify a peptide corresponding to ODO2 
which was not identified using the GRCh37 human reference database, demonstrating 
the utility of proteogenomics in cancer research. Without utilizing a proteogenomic 
approach, the finding of an unreported peptide would have been lost between the 
transcriptomic and proteomic data, overlooking a potentially significant finding. The 
ability to append protein databases to include peptides predicted to be present in a 
sample based on RNA-seq data is a crucial crossover between transcriptomics and 
proteomics, and provides a deeper understanding of potential drivers of cancer 






CHAPTER 4. SUMMARY AND FUTURE DIRECTIONS 
The work in this thesis provides many avenues to explore potentially novel mechanisms 
of imatinib, nilotinib, and dasatinib resistance in a cell-culture model of evolved 
resistance using K562 cells. In chapter 2, we describe the use of RNA-seq to identify 
differences in transcript expression in K562-IR, K562-NR, and K562-DR cells with respect 
to the parental K562 cell line, and then distinguish transcripts that are differentially 
expressed across all three TKI-resistant cell lines as compared to the parental K562 cell 
line, which suggest potential avenues for future research into general mechanisms of 
TKI-resistance in a CML cell-culture model. We also describe the differences in 
transcriptexpression within each individual cell line, which serves to highlight the 
different evolutionary pressures that an individual TKI can exert on a cell line, and how 
an individual TKI can affect the acquisition of a resistant phenotype through the 
alteration of differential expression of a wide variety of genes, ultimately leading to 
resistance.   
 
We identified several genes we suspected might be involved in general TKI-resistance, 






imatinib and nilotinib resistance, presumably through a scaffolding function that 
allowed for compensatory activation of LYN kinase[42], and the ablation of the AXL 
transcript restored sensitivity to imatinib and nilotinib in resistant cell lines to a level 
comparable to the parental K562 cell line, which served as an internal control to validate 
our cell culture model as a clinically-relevant model of acquired TKI-resistance. However, 
the K562-DR cell line did not sharply respond to AXL ablation in the same manner as the 
K562-IR and K562-NR cell lines did, suggesting that the mechanisms underlying dasatinib 
resistance are not AXL-dependent. It is interesting to note that AXL upregulation at the 
transcript level correlates with the downregulation of many proteins involved in the 
formation of the desmosome complex. The desmosome complex is integral in cell-cell 
adhesion and the loss of the proteins involved in the formation of the desmosome 
complex could serve as a biomarker of imatinib resistance.  
 
The ablation of ACP5 had a similar effect on the proliferation of K562-IR and K562-NR 
cells, restoring sensitivity to imatinib and nilotinib, respectively. However, the K562-DR 
cells again did not have a significant response to ACP5 ablation, signifying that dasatinib 
resistance is mediated through an alternative mechanism, and ACP5 upregulation may 







The ablation of CYP2S1 in K562-IR cells dramatically increased sensitivity to imatinib, but 
increased resistance to imatinib in K562 cells. This seemingly illogical result underscores 
the complexity of drug-metabolism, and eliminates CYP2S1 as a serious candidate for 
further study. Ablation of CYP2S1 in K562-NR cells had a similar effect, though less 
pronounced. In K562-DR cells, the ablation of CYP2S1 slightly sensitized the cells to 
dasatinib, although the results mirror the effects of ablating AXL and ACP5 from 
previous experiments. The results of this RNA-seq study did not elucidate any promising 
mechanisms of resistance to dasatinib.  
 
One of the advantages of RNA-seq is the ability to detect minor changes in the 
transcription profile between samples. We were able to detect the transcription of 
genes that were not present in the parental K562 sample, or the total loss of 
transcription in the TKI-resistant cell line. We identified a massive upregulation in 
transcription of miRNA3940 and miRNA637, and SNORD88A and SNORD88B in K562-IR 
cells, and massive upregulation of SNORD33 and SNORD35A in K562-NR cells, yet a 
massive downregulation of SNORD88C in K562-NR and K562-DR cells. At this time, there 
is little known about the function of any of these transcripts, but there has been several 
reports that indicate miRNA’s and snORD’s play a role in translational regulation, which 
may partially explain the lack of correlation between the transcriptome and proteome, 






miRNA and snORDS may be useful information for future studies to follow up on the 
emergence or disappearance of these transcripts with regards to TKI-resistance.  
 
Finally, we described the detection of novel fusion transcripts emergent in our TKI-
resistant cells. Fusion genes are responsible for many disease pathologies, CML being 
one of them. Detection of novel fusion genes is integral to the characterization of 
disease pathology, especially in drug resistance, as the detection of these transcripts 
could help predict future resistance to chemotherapy and guide therapeutic regimens 
for patients. 
 
In the third chapter, we used SWATH-MS to profile the proteomic differences between 
K562 parental cells and the TKI-resistant cells we have generated in-house. The 
significantly differentially expressed proteins in our K562-IR cell line alluded to the loss 
of the desmosome as a biomarker of TKI-resistance, as we observed the loss of eleven 
proteins composing the desmosome, a structure that mediated cell-cell adhesion, and 
the loss of which is a hallmark of CML progression. K562-NR cells showed a loss of 
proteins involved with the regulation of cellular metabolism, suggesting that chronic 
nilotinib exposure has a role in rewiring the metabolic functions of K562 cells, conferring 
resistance to nilotinib. Dasatinib-resistant K562 cells showed a very similar protein 






some role in metabolism. Overall, eighteen proteins were commonly differentially 
expressed at a log2 fold change of ±1 between the three TKI-resistant cells, including 
PHB2, CAST, NUCKS1, DDX6, and DDX21. PHBS was significantly unregulated, and has 
been shown to be involved in apoptosis resistance, cell-cycle checkpoint release, and 
ERK1/2 signaling. CAST and NUCKS1 are known biomarkers of oncogenesis in many 
other cancers, so it may be worth tracking their protein expression in chemoresistant 
cells as biomarkers of TKI-resistance in CML. We also identified the upregulation of 
DDX6 and DDX21, proteins involved in translation of mRNA, which could partially 
explain the lack of correlation between the transcriptomic and proteomic data. 
 
 Lastly, we used a proteogenomic approach to identify novel peptides in TKI-resistant 
cells. We were able to identify one novel mutant peptide, corresponding to the ODO2 
gene that was not represented in the canonical GRCh37 FASTA database, and contained 
a lysine-proline mutation from the mRNA to protein level. The ability to add a layer of 
information blending transcriptomic and proteomic data is critical to understanding 
complex pathological phenotypes, and this data demonstrates the power of the 
proteogenomic approach in cancer research.  
 
Optimization of SWATH-MS methods will certainly increase the coverage of protein 






identification. The results of the data reported in this thesis suggest several promising 
therapeutic avenues to explore, but there is room to improve. First and foremost, the 
SWATH-MS methodology needs to be optimized, specifically the need for up-front 
fractionation and a longer HPLC gradient. These factors will certainly improve the 
identification of proteins, and allow a more accurate comparison of our results to our 
RNA-seq data. It is clear that there is little correlation between the transcriptome and 
proteome of our K562-TKI resistant cells, and protein levels in a cell do not yield any 
information about the activity of those proteins. Moving forward, a major effort will be 
made to understand the post-translational modifications that dictate the activity of the 
signaling proteins in our K562-TKI resistant cells. By enriching for phospho-peptides we 
will be able to construct a map of the signaling events underlying chemoresistance in 
our model of acquired TKI-resistance, which will be more informative than the 
transcriptome or proteome alone.  
 
The goal of this research is to identify biomarkers of resistance and propose novel 
resistance mechanisms, and the best way to understand the dynamics of how a cell 
responds to a stimulus is by integrating multiple layers of information to determine 
which genes are transcribed, which proteins are translated, and how post-translational 
modification of proteins effect the molecular signaling pathways underlying TKI-
resistance. In this thesis we have described the transcriptional and translational levels; 







comprehensive characterization of the phospho-proteome in our model cell lines. The 
findings of our research must then be compared to human patient samples to validate 
our findings. The findings of this thesis have shined a light on many paths leading to the 
acquisition of chemoresistance. As Rosalia de Castro once said, “We can see the path, 
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